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RNA NANOPARTICLES FOR BRAIN TUMOR 
TREATMENT 
RELATED APPLICATIONS 
This application is a § 371 National State Application of 
PCT/US2016/021447 filed Mar. 9, 2016 which claims the 
benefit of U.S. Provisional Patent Application No. 62/130, 
459, filed Mar. 9, 2015, the entire disclosures of which are 
hereby incorporated by reference in their entirety. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
CA151648 (P.G.), EB012135 (P.G.), CA152758 (C.M.C.), 
CAI 75875 (I.N.), CA163205 (I.N.), P30NS045758 (B.K.), 
R01064607 (B.K.), R01CA150153 (B.K.), and 
P01CA163205 (B.K.) awarded by the National Institutes of 
Health. The govermnent has certain rights in the invention. 
SEQUENCE LISTING 
2 
intermolecular base-pairing via the interaction of two inter-
locking loops, the pRNA molecules form dimers, trimers, 
hexamers, and patterned superstructures [7]. This property 
of forming self-assembled nano structure makes pRNA ideal 
5 building blocks for bottom-up assembly. RNA nanotechnol-
ogy has been rapidly growing as a new generation platform 
for biological and medical application (2-3). As nanotech-
nology rapidly evolves, many attempts have been made to 
deliver small interfering RNA (siRNA) using viruses, lipo-
10 some, lipid, and polymer based nanoparticles ( 4). 
Clearly there remains a need for improved composition 
and methods targeting both brain tumor cells and glioblas-
toma stem cells to treat the primary brain tumor and prevent 
tumor recurrence is desired. The presently disclosed subject 
15 matter relates to RNA nanoparticle containing compositions 




The instant application contains a Sequence Listing which 
has been submitted electronically in ASCII format and is 
hereby incorporated by reference in its entirety. Said ASCII 25 
copy, created on Mar. 30, 2018, is named 2935720-7 SL.txt 
and is 4,791 bytes in size. 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-TECHNICAL FIELD 
The presently-disclosed subject matter relates to an arti-
ficial RNA nanostructure molecule and method to treat brain 
tumor in a subject. More particularly, the presently disclosed 
subject matter relates to a RNA nanostructure containing a 
multiple branched RNA nanoparticle, a brain tumor target-
ing module, and an effective amount of a therapeutic agent. 
Further, the presently disclosed subject matter relates to a 
method of using the RNAnanostructure composition to treat 
brain tumor in a subject having or at risk of having brain 
tumor. 
INTRODUCTION 
The most common primary brain tumors in adults are 
glioblastomas, which are also one of the most deadly cancers 
(1). For glioblastomas, conventional treatment involves sur-
gical resection followed by radiation and concurrent che-
motherapy. Even with this treatment regimen, the median 
survival of patients with glioblastoma is less than 15 months. 
The poor prognosis is primarily due to tumor recurrence, 
which is thought to originate from a subset of cancer stem 
cells that survive the primary treatments. Recent studies 
suggested that glioblastoma stem cell survived the therapeu-
tic stresses and become more aggressive when they recur, 
developing resistance to the primary chemotherapy. 
30 tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the fea-
ture(s) mentioned; likewise, those features can be applied to 
other embodiments of the presently-disclosed subject mat-
ter, whether listed in this Summary or not. This Summary 
35 does not list or suggest all possible combinations of such 
features. 
In some embodiments, the presently disclosed subject 
matter provides an artificial RNA nanostructure molecule. 
The molecule includes a multiple branched RNA junction 
40 motif comprising at least one RNA oligonucleotide, and a 
brain tumor targeting module, and the module is coupled to 
an RNA junction motif. In some embodiments, the molecule 
further includes at least one bioactive agent coupled to the 
RNA junction motif. A non-limiting example of the bioac-
45 tive agent is a a therapeutic agent. In some embodiments, the 
RNA oligonucleotide is at least 6 nucleotides in length. In 
some embodiments, the RNA oligonucleotide includes at 
least one chemical modification at the 2' position. Non-
limiting examples of the chemical modification include 
50 2'Fluoro, 2'Amine, 2'O-Methyl, or a combination thereof. 
In some embodiments, the multiple branched RNA 
includes a nucleotide sequence 5'-UUG CCA UGU GUA 
UGU GGG AUC CCG CGG CCA UGG CGG CCG GGA 
G-3' (SEQ ID NO: 6). In some embodiments, the multiple 
55 branched RNA includes a sequence 5' GATAAGCT CTC 
CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID NO: 
7). In some embodiments, the multiple branched RNA 
junction motif is a three-branched RNA junction motif. In 
Bacterial virus phi29 DNA packaging RNA (pRNA) 
molecule is a crucial component in the phi29 DNA pack-
aging motor and contains two functional domains. The 
intermolecular interaction domain is located at the central 
region (bases 23-97) and within this domain there are two 60 
loops (right hand loop and left hand loop) which are respon-
sible for the hand-in-hand interaction through the four 
complementary base sequences within these two loops. The 
other domain is a DNA translocation domain which is 
located at the 5'/3' paired ends. The right hand loop (bases 65 
45-48) and the left hand loop (bases 82-85) allow for the 
formation of pRNA dimers, trimers and hexamer rings via 
some embodiments, the three-branched RNA junction motif 
includes a packaging RNA (pRNA) three-way junction 
(3WJ) motif. In some embodiments of the present disclo-
sure, the RNA molecules form dimers, trimers, hexamers, 
and patterned superstructures. 
In some embodiments, the presently disclosed subject 
matter provides that a branch of the three-branched RNA 
junction motif includes an a3WJ RNA module. In some 
embodiments, a branch of the three-branched RNA junction 
US 10,584,144 B2 
3 
motif includes a b3 WJ RNA module. In some embodiments, 
a branch of the three-branched RNA junction motif includes 
4 
cell proliferation pathway proteins, anti-apoptotic pathway 
proteins, or a combination thereof. In further embodiments, 
the mRNA molecule encodes a protein including but not 
limited to VEGF pathway proteins, EGFR pathway proteins, 
a c3WJ RNA module. In some embodiments, the three-
branched RNA junction motif includes an a3WJ RNA 
module, a b3WJ RNA module, and a c3WJ RNA module. A 
non-limiting example of RNA module include nucleotide 
sequences 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID 
NO: 1 ), 5'-CCC ACA UAC UUU GUU GAUCC-3' (SEQ ID 
NO: 2), and 5'-GGA UCA AUC AUG GCA A-3' (SEQ ID 
NO: 3). 
5 MGMT pathway proteins, Rafi pathway proteins, MMP 
pathway proteins, mTOR pathway proteins, TGF~ pathway 
proteins, or Cox-2 pathway proteins, or a combination 
thereof. In some embodiments, non-limiting examples of 
protein include VEGF, EGFR, POK, AKT, AGT, RAF, RAS, 
In some embodiments, the diameter of the molecule is at 
least about 40 nm or less. In some embodiments, the 
diameter of the molecule is at least about 30 nm or less. In 
some embodiments, the diameter of the molecule is at least 
about 15 nm or less. 
10 MAPK, ERK, MGMT, MMP-2, MMP-9, PDGF, PDGFR, 
IGF-I, HGF, mTOR, Cox-2 and TGF~l. In some embodi-
ments, the siRNa binds to a mRNA molecule that encodes 
RAS, cMET, HER2, MDM2, PIK3CA, AKT, CDK4, or a 
combination thereof. 
In some embodiments, the RNA molecule has a zeta 
potential ranging from about -50 mV to about 50 mV. In 
some embodiments, the molecule has a zeta potential rang-
ing from about -25 my to about 25 mV. 
15 
In some embodiments, the presently disclosed subject 20 
matter provides that the brain tumor targeting module in the 
artificial RNA nano structure molecule includes a ligand that 
binds to at least one brain tumor cell surface marker. 
Non-limiting examples of the brain tumor surface marker 
includes folate receptor, EGFR, transferrin receptor, and an 25 
RGD. In some embodiments, the ligand includes an aptamer. 
Further provided, in some embodiments of the presently 
disclosed subject matter, is a nucleic acid composition. The 
composition includes a therapeutically effective amount of 
the artificial RNA nanostructure molecule as disclosed 
above. In some embodiments, the composition includes a 
pharmaceutically acceptable carrier. 
Still further, the presently disclosed subject matter, in 
some embodiments, provides a nanoparticle delivery sys-
tem. The delivery system includes the artificial RNA nano-
structure molecule as disclosed above. In some embodi-
ments, the nanoparticle delivery system further includes a 
pharmaceutically acceptable carrier. 
In another aspect, the presently disclosed subject matter 
provides, in some embodiments, a method of treating a brain 
tumor in a subject having or at risk of developing a brain 
In some embodiments, the aptamer binds to EGFR, PDGFR, 
folate receptor, or a combination thereof. In some embodi-
ments, In some embodiments, the targeting module is a 
folate. 30 tumor. The method includes administering to the subject a 
therapeutically effective amount of a composition compris-
ing an artificial RNA nanostructure molecule as disclosed 
herein. In some embodiments, the composition includes a 
pharmaceutically acceptable carrier. In some embodiments, 
In some embodiments, the presently disclosed subject 
matter provides a bioactive agent includes a drug, a fluo-
rescent dye, a chemical, or a combination thereof. In some 
embodiments, the bioactive agent includes a siRNA, a 
miRNA, an anti-miRNA, a ribozyme RNA, an antisense 
RNA, or a combination thereof. In some embodiments, the 
bioactive agent is directed to a brain tumor marker. Non-
limiting examples of the bioactive agent include siRNA 
sequence and microRNA sequence. In some embodiments, 
the microRNA molecule is at least 3 nucleotide in length. In 
some embodiments, the bioactive agent is an anti-miRNA 
molecule for a miRNA encoding miR-9, miR-l0b, miR-21, 
miR-17, or miR-26. In some embodiments, the bioactive 
agent is a miRNA molecule for a miRNA encoding let-7a, 
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miR- 45 
181b. In some embodiments, the miRNA includes miRNA 
locked nucleic acid (LNA) molecule. In some embodiments, 
the microRNA sequence is an anti-miR-21 sequence. In 
some embodiments, non-limiting examples of the miRNA 
sequence comprises 5'-GATAAGCT-3', 5'-AGCACTTT-3', 50 
or 5'-ATTTGCAC-3'. In some embodiments, the miRNA 
includes an miRNA locked nucleic acid (LNA) molecule. In 
some embodiments, the bioactive agent includes a LNA 
miRNA molecule 5'-+G+A+T+A+A+G+C+T-3'. In some 
embodiments, miRNA LNA molecule includes a sequence 
5'-+A+G+C+A+C+T+T+T-3'. In some embodiments, 
miRNALNAmolecule includes a sequence 5'-+A+T+T+T+ 
G+C+A+C-3'. 
In some embodiments, the microRNA is a locked nucleic 
acid (LNA) sequence. In some embodiments, the microRNA 
is a LNA-miR21 sequence 5'-+G+A+T+A+A+G+C+T-3'. In 
some embodiments, the siRNA binds to a mRNA sequence 
of a gene that promotes tumorigenesis, angiogenesis, cell 
proliferation, or a combination thereof, in the brain or spinal 
cord. In some embodiments, the siRNA binds to a mRNA 
molecule that encodes a protein including pro-tumorigenic 
pathway proteins, pro-angiogenesis pathway proteins, pro-
35 the subject is a mammal or a non-mammal vertebrate. In 
some embodiments, the subject is a human. In some embodi-
ments, the brain tumor is glioblastoma. 
Further, in some embodiments, the present disclosure 
provides a method of preventing brain tumor recurrence a 
40 subject having or at risk of having brain tumor recurrence. 
The method includes administering to the subject a thera-
peutically effective amount of a composition comprising an 
artificial RNA nanostructure molecule as disclosed herein. 
In some embodiments, the composition includes a pharma-
ceutically acceptable carrier. In some embodiments, the 
subject is a mammal or a non-mammal vertebrate. In some 
embodiments, the subject is a human. In some embodiments, 
the brain tumor is glioblastoma. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The features of the presently disclosed subject matter are 
set forth with particularity in the appended claims. A better 
understanding of the features and advantages of the pres-
55 ently disclosed subject matter will be obtained by reference 
to the following detailed description that sets forth illustra-
tive embodiments, in which the principles of the subject 
matter are used, and the accompanying drawings of which. 
The drawings were originally published in color, incorpo-
60 rated by reference in their entireties (Tae Jin Lee, et al. 
(2015) Oncotarget, Vol. 6, No. 17, 14766-14776). The black 
and white drawings of the instant application correspond to 
the color ones published. 
FIGS. lA-lD are diagrams and images illustrating con-
65 struction and characterization of multi-functional pRNA-
3WJ RNP for glioblastoma cell targeting. A, Construction 
map of trivalent FA-Alexa647-pRNA-3WJ-si(Luc) RNP 
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harboring three functionalities to form: Folate (FA) as a 
targeting ligand; Alexa647 as an imaging module; and 
luciferase siRNA for gene silencing. FIG. lA discloses SEQ 
ID NOS 19, 3, 2 and 5, respectively, in order of appearance. 
6 
from 1123 cells was evaluated by MRI for tumor size 
determination (top). After systemic administration ofFA-Al-
exa647-pRNA-3WJ RNP, FA-dependent targeting was visu-
B, Atomic force microscopy (AFM) image showing three- 5 
branched triangular structure of self-assembled trivalent 
FA-pRNA-3WJ-si(Luc) RNP. C, Dynamic light scattering 
(DLS) data showing the size of FA-pRNA-3WJ-si(Luc) 
RNP. D, Zeta potential ofFA-pRNA-3WJ-si(Luc) RNP. The 
data in C and D were obtained from three independent 10 
alized by fluorescence in vivo imaging in comparison to 
FA-free Alexa647-pRNA-3WJ RNP. C, Biodistribution pro-
file of FA-Alexa647-pRNA-3WJ RNP was obtained by 
imaging fluorescence against Alexa647 from major internal 
organs collected together with brain. 
FIG. 5 is graphs illustrating flow cytometry analysis for 
FA-mediated human glioblastoma cell targeting by FA-Al-
exa647-pRNA-3WJ RNP in vitro. Human glioblastoma cells 
U87EGFRvIII were pre-treated with 1 mM free folate in 
culture media for 1 hr before incubation with FA-Alexa647-
pRNA-3WJ RNP containing medium. Events as a function 
of Alexa647 signal intensity detected from U87EGFRvIII 
experiments. 
FIGS. 2A-2D are graphs and images showing FA-medi-
ated human glioblastoma cell targeting by FA-Alexa647-
pRNA-3WJ RNP in vitro and in vivo. A, Flow cytometry 
analysis for FA-dependent human glioblastoma cell 
U87EGFRvIII targeting in vitro by FA-Alexa647-pRNA-
3WJ RNP. Alexa647 signals from U87EGFRvIII cells 
treated with 200 nM ofFA-Alexa647-pRNA-3WJ RNP were 
compared to control RNP (FA-free Alexa647-pRNA-3WJ 
RNP) normalized to PBS control. Percentage of cell popu-
lations were analyzed by student t-test (p<0.001, n=4). B, 
Immunofluorescence confocal microscopy for FA-depen-
dent human glioblastoma cell U87EGFRvIII targeting in 
vitro by FA-Alexa647-pRNA-3WJ RNP (middle) in com-
parison to control RNP (FA-free Alexa647-pRNA-3WJ) 
(top) or 1 mM free folate pre-treated cells in culture media 
(bottom). Pseudocolor was used for nucleus (blue), cyto-
skeleton (green) and Alexa647 (red). C, U87EGFRvIII-
induced brain tumors in mice targeted by FA-Alexa647-
pRNA-3WJ RNP. Tumors were determined by MRI (yellow 
arrows in top panel) and visualized by fluorescence in vivo 
imaging (bottom panel) after tail vein injection of FA or 
FA-freeAlexa647-pRNA-3WJ RNP. Representative images 
from each group of 4 were displayed. D, ANOVA analysis 
on fluorescence intensity of Alexa647 normalized by tumor 
volume (mm3 ), p=0.019 (n=4). 
FIGS. 3A-3E are graphs and images showing gene silenc-
ing effect of FA-pRNA-3WJ-si(Luc) RNP in human glio-
blastoma cells and derived tumor. A, A wide range (up to 400 
nM) of FA-pRNA-3WJ-si(Luc) (closed circles) or 
FA-pRNA-3WJ-si(Scrm) (negative control, open circles) 
RNPs were incubated with U87EGFRvIII-Luc cells in vitro 
(n-=4). The change of luciferase activity was monitored 
versus the concentration of the RNPs. B, Luciferase gene 
silencing effect ofFA-pRNA-3WJ-si(Luc) in vivo after total 
of three injections. Luciferase activity change by FA-pRNA-
3WJ-si(Luc) (closed circles) or FA-pRNA-3WJ-si(Scrm) 
( open circles) were compared by mean bioluminescence 
intensity (n=5), p=0.007. C, Representative in vivo MRI 
images for tumor volume and bioluminescence intensity for 
luciferase activity from both FA-pRNA-3WJ-siRNA(Luc) 
15 cells treated with 200 nM ofFA-Alexa647-pRNA-3WJ RNP 
were compared to control RNP (FA-free Alexa647-pRNA-
3WJ RNP). The figure is representative of three experi-
ments. 
FIG. 6 contains images showing FA-mediated human 
20 glioblastoma cell T98G in vitro targeting by FA-Alexa647-
pRNA-3WJ RNPs. Glioblastoma multiforme (GBM) cell 
line, T98G, was treated with 200 nM of FA-Alexa647-
pRNA-3WJ or Alexa647-pRNA-3WJ for 1 hr, followed by 
fluorescence confocal microscopy. Pseudocolor was used for 
25 nuclear (blue), cytoskeleton (green) and Alexa647 (red). 
FIG. 7 includes images showing confocal fluorescence 
imaging of frozen sectioned brain tumor derived from 
human glioblastoma patient-derived stem cell 1123 demon-
strating the distribution and accumulation of FA-Alexa647-
30 pRNA-3WJ RNP in brain tumor cells (yellow arrows). 
Pseudocolor was used for nuclear (blue), and Alexa647 
(red). 
FIG. 8 includes images showing human glioblastoma 
patient-derived stem cell 1123-derived mouse brain tumor 
targeting by FA-Alexa647-pRNA-3WJ RNPs with RNA 
35 dose-dependent (100>20 µg/mouse) manner. The fluores-
cence intensity for the tumor-bearing mouse brains were 
evaluated at 15 hrs after systemic injection of RNPs. 
FIG. 9A is a diagram illustrating the construction map of 
trivalent FA-3WJ-LNA-miR21. FIG. 9A discloses SEQ ID 
40 NOS 6, 3, 2 and 7, respectively, in order of appearance. FIG. 
9B includes graphs illustrating FA-mediated in vitro human 
glioblastoma cell targeting determined by flow cytometry. 
FIG. 10 includes images showing FR-dependent human 
glioblastoma cell targeting visualized by confocal fluores-
45 cent microscopy. 
FIG. 11 includes images showing confocal fluorescent 
microscopy analysis visualizes human glioblastoma cell 
specific distribution. 
FIG. 12 includes graphs and images showing anti-tumor 
effect of systemically delivered FA-3WJ-LNA-miR21 RNP 
50 in human glioblastoma cells derived tumor in vivo. 
or FA-pRNA-3WJ-si(Scrm) after three injections. D, Tumor 
volumes calculated from MRI compared to scrambled con-
trol group at day 13 post-xenograft, p=0.468 (n=5). E, Mean 
fluorescence intensity divided by tumor volume (mm3 ) was 55 
used to normalize the variation among the tested mice, 
p=0.015 (n=5). All error bars indicate s.e.m., and student 
t-test was used for statistical analysis. 
FIG. 13 is a graph illustrating knock-down of endogenous 
miR-21 in mouse tumor by systemically delivered FA-3WJ-
LNA-miR21. 
FIGS. 14Aand 14B are graphs and images showing down 
regulation of miR-21 by systemically delivered FA-3WJ-
LNA-miR21 induced apoptotic pathway through recovery 
of Pten protein expression. 
FIG. 15 is a graph showing knock-down of endogenous 
miR-21 in mouse tumor by systemically delivered FA-3WJ-
LNA-miR21 improved overall survival of brain tumor-
bearing mice. 
FIGS. 4A-4C are graphs and images showing FA-medi-
ated targeting of human glioblastoma patient-derived stem 60 
cell and derived brain tumor by FA-Alexa647-pRNA-3WJ 
RNPs in animal trials and biodistribution study. A. Flow 
cytometry analysis for in vitro targeting of human glioblas-
toma patient-derived stem cell, 1123, by FA-Alexa647-
pRNA-3WJ or Alexa647-pRNA-3WJ RNP co-treated with 65 
CD44-FITC antibody. PBS and CD44-FITC treated cells 
were used as gating controls. B, Mouse brain tumor derived 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
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Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem- 5 
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. 
In certain instances, nucleotides and polypeptides dis-
closed herein are included in publicly-available databases, 10 
such as GENBANK® and SWISSPROT. Information 
8 
ther, the presently disclosed subject matter relates to a 
method of using the RNA nano structure composition to treat 
brain tumor in a subject having or at risk of having brain 
tumor. 
In some embodiments, the presently disclosed subject 
matter provides an artificial RNA nanostructure molecule. 
The molecule includes a multiple branched RNA junction 
motif comprising at least one RNA oligonucleotide, and a 
brain tumor targeting module, and the module is coupled to 
an RNA junction motif. In some embodiments, the molecule 
further includes at least one bioactive agent coupled to the 
RNA junction motif. In some embodiments, the RNA oli-
gonucleotide is at least about 6 nucleotides in length. 
RNA nanotechnology has recently emerged as an impor-
including sequences and other information related to such 
nucleotides and polypeptides included in such publicly-
available databases are expressly incorporated by reference. 
Unless otherwise indicated or apparent the references to 
such publicly-available databases are references to the most 
recent version of the database as of the filing date of this 
Application. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
15 tant field due to recent finding of its high thermodynamic 
stability, favorable and distinctive in vivo attributes (US 
2014/0179758, hereby incorporate by reference in its 
entirety). In some embodiments of the present disclosure, as 
disclosed in US2014/0179758, the RNA molecules form 
20 dimers, trimers, hexamers, and patterned superstructures. 
Further, RNA nanoparticles can be fabricated with precise 
control of shape, size and stoichiometry, as demonstrated by 
the packaging RNA (pRNA) of the bacteriophage phi29 
DNA packaging motor, which forms dimmers, trimers, and 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
25 hexamers via hand-in-hand interactions of the interlocking 
loops. 
In some embodiments, the presently disclosed subject 
matter relates to a RNA nanoparticle based composition. 
Such nanoparticles is delivered systemically and specifically of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
30 target intracranial tumors with minimal toxicity. In some 
embodiments, the nanoparticle relates to a pRNA three-way 
junction (pRNA-3WJ). The pRNA-3WJ of the bacterio-
phage phi29 DNA packaging motor can be used to fabricate 
a RNA nanoparticle (RNP) with precise control of shape, 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
35 size and stoichiometry (4-10). Creation of boiling resistant 
RNPs with controllable shapes and defined stoichiometry 
has been recently reported (11). 
The term "RNA" refers to a molecule comprising at least 
one ribonucleotide residue. By "ribonucleotide" is meant a 
40 nucleotide with a hydroxyl group at the 2' position of a 
~-D-ribofuranose moiety. The terms encompass double 
stranded RNA, single stranded RNA, RNAs with both 
double stranded and single stranded regions, isolated RNA 
such as partially purified RNA, essentially pure RNA, 
45 synthetic RNA, recombinantly produced RNA, as well as 
altered RNA, or analog RNA, that differs from naturally 
occurring RNA by the addition, deletion, substitution, and/or 
alteration of one or more nucleotides. Such alterations can 
include addition of non-nucleotide material, such as to the 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. As used 
herein, ranges can be expressed as from "about" one par-
ticular value, and/or to "about" another particular value. It is 
also understood that there are a number of values disclosed 55 
herein, and that each value is also herein disclosed as 
"about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
50 end(s) of an siRNA or internally, for example at one or more 
nucleotides of the RNA. Nucleotides in the RNA molecules 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 60 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently-disclosed subject matter relates to RNA 
nanostructure molecule and method to treat brain tumor in a 
subject. More particularly, the presently disclosed subject 65 
matter relates to a molecule containing a multiple branched 
RNA junctive motif, a brain tumor targeting module. Fur-
of the presently disclosed subject matter can also comprise 
non-standard nucleotides, such as non-naturally occurring 
nucleotides or chemically synthesized nucleotides or deoxy-
nucleotides. These altered RNAs can be referred to as 
analogs or analogs of a naturally occurring RNA. 
In some embodiments, the RNA oligonucleotide of the 
RNA nanoparticles includes at least one chemical modifi-
cation at the 2' position. Non-limiting examples of the 
chemical modification include 2'Fluoro, 2'Amine, 2'O-
Methyl, or a combination thereof. In one embodiments, the 
pRNA-3WJ nanoparticles with 2'-Fluoro (2'-F) modifica-
tions of U and C nucleotides renders the RNPs resistant to 
RNase degradation enhancing their in vivo half-life while 
retaining authentic functions of the incorporated modules (7, 
12, 13). Furthermore, the pRNA-3WJ RNPs were non-toxic, 
non-immunogenic, and displayed favorable biodistribution 
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and pharmacokinetic profiles in mice (14). These favorable 
characteristics make this novel platform attractive for the 
systemic delivery of siRNA to glioblastoma. One promising 
ligand for nanoparticle therapy in glioblastoma targeting is 
folate, a natural member of the B-vitamin family. Folate is 
required for early neuronal development and differentiation 
(15). Its transportation across the blood-cerebrospinal fluid 
barrier (BCSF) occurs by the choroid plexus (16). The 
choroid plexus expresses the largest amount of folate recep-
10 
interest (e.g., storage at a particular temperature for a 
particular time period) (test sample), making an assessment 
of the test sample, and comparing the assessment of the 
control sample to the assessment of the test sample. Calcu-
5 lations can be made to determine whether the amounts 
present in the test sample are 100%±20, 19, 18, 17, 16, 15, 
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the 
amount that is in the control sample. 
tor (FR) in a body, while no FR expression is detected in 10 
cerebellum, cerebrum or spinal cord (17,18). 
In some embodiments, the presently disclosed subject 
matter provides that the brain tumor targeting module in the 
artificial RNA nano structure molecule includes a ligand that 
binds to at least one brain tumor cell surface marker. As used 
In some embodiments, the multiple branched RNA 
includes a nucleotide sequence 5'-UUG CCA UGU GUA 
UGU GGG AUC CCG CGG CCA UGG CGG CCG GGA 
G-3' (SEQ ID NO: 6). In some embodiments, the multiple 
branched RNA includes a sequence 5'-GATAAGCT CTC 
CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID NO: 
7). In some embodiments, the presently disclosed subject 
matter provides that a branch of the three-branched RNA 
junction motif includes an a3WJ RNA module. In some 
embodiments, a branch of the three-branched RNA junction 
motif includes a b3 WJ RNA module. In some embodiments, 
a branch of the three-branched RNA junction motif includes 
a c3WJ RNA module. In some embodiments, the three-
branched RNA junction motif includes an a3WJ RNA 
module, a b3WJ RNA module, and a c3WJ RNA module. A 
non-limiting example of RNA module include nucleotide 
sequences 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID 
NO: 1 ), 5'-CCC ACA UAC UUU GUU GAUCC-3' (SEQ ID 
NO: 2), and 5'-GGA UCA AUC AUG GCA A-3' (SEQ ID 
NO: 3). 
In some embodiments, the diameter of the molecule is at 
least about 40 nm or less. The diameter is at least about 35 
nm or less, at least about 30 nm or less, at least about 25 nm 
or less, at least 20 nm or less, at least 15 nm or less, at least 
10 nm or less, at least 5 nm or less. 
In some embodiments, the molecule has zeta potential 
ranging from about -150 m V to about 150 m V. The RNA 
molecule has a zeta potential ranging from about -140 mV 
to about 140 mV, from about -130 mV to about 130 mV, 
from about -120 m V to about 120 m V, from about -110 m V 
to about 110 mV, from about -100 mV to about 100 mV, 
from about -90 to about 90 m V, form about -80 m V to about 
80 m V, from about - 70 m V to about 70 m V, from about -60 
herein, cell surface markers include any cellular component 
15 
that may be detected within or on the surface of a cell, or a 
macromolecuie bound or aggregated to the surface of the 
cell. As such, cell surface markers are not limited to markers 
physically on the surface of a cell. For example, cell surface 
markers may include, but are not limited to surface antigens, 
20 transmembrane receptors or coreceptors, macromolecules 
bound to the surface, such as bound or aggregated proteins 
or carbohydrates, internal cellular components, and the like. 
Non-limiting examples of the brain tumor surface marker 
includes folate receptor, EGFR, transferrin receptor, and an 
25 RGD. In some embodiments, the ligand includes an aptamer. 
In some embodiments, the aptamers binds against EGFR, 
PDGFR, or folate receptor. In some embodiments, the 
targeting module is a folate. 
In some embodiments, a brain tumor targeting module is 
30 coupled to the RNA nanoparticle. The targeting module 
direct the nanoparticle to the brain tumor cells, to enhance 
binding to them, to enhance internalization, to enhance 
targeting to cellular enzymes, DNA, RNA, proteins, lipids, 
35 
or carbohydrates. Non-limiting examples of the brain tumor 
targeting module are antibodies, antibody fragments, poly-
peptides, cell ligands, aptamers, DNA. RNA, drugs, com-
pounds that enhance targeting the brain tumor cell, and other 
groups or materials that enhance binding to brain tumor 
40 cells. 
m V to about 60 m V. In some embodiments, the RNA 45 
molecule has a zeta potential ranging from about -50 m V to 
about 50 m V. The molecule has a zeta potential ranging from 
about -45 my to about 45 m V, from about -40 m V to about 
In some embodiments, a brain tumor targeting module 
may be an antibody. The antibody may have an ability to 
recognize and specifically bind to a target on tumor cells and 
tissues. Non-limiting example of the antibody is an antibody 
configured to specifically bind a protein selected from but 
not limited to EGFR, human epidermal growth factor 
(HER), laminin 411, insulin-like growth factor (IGF) and 
tumor necrosis factor-alpha (TNF-a). 
40 m V, from about -35 m V to about 35 m V, from about -35 
mV to about 30 mV, from about -35 mV to about 20 mV, 50 
from about -25 mV to about 15 mV. 
In some embodiments, a targeting module is an antibody 
of a class described as antagonist antibodies, which specifi-
cally bind to a brain tumor stem cell marker protein and 
interfere with, for example, ligand binding, receptor 
dimerization, expression of a brain tumor stem cell marker 
protein, and/or downstream signaling of a cancer stem cell 
In some embodiments, the RNA nanostructure molecule 
is substantially stable in pH ranges from about 2 to about 13. 
The RNA molecule is substantially stable in pH about 2, 3, 
4, 5, 6, 7, 8, 9, 10, 11, 12 and 13. As used herein, the term 
"substantially stable" can refer to physical and/or chemical 
stability. As will be recognized by those of ordinary skill in 
the art, the term "substantially stable" can refer to stability 
of the composition under certain conditions, relative to an 
initial composition (i.e., when a particular batch of the 
composition is initially prepared). In this regard, as will be 
recognized by those of ordinary skill in the art, one manner 
in which stability of a particular embodiment of the com-
position can be determined is as follows: preparing a batch 
55 marker protein. Yet in other embodiments, a targeting mod-
ule is an antibody of a class described as agonist antibodies 
which specifically bind to a brain tumor stem cell marker 
protein and promote, for example, ligand binding, receptor 
dimerization, and/or signaling by a cancer stem cell marker 
60 protein. Yet in further embodiments, a targeting module is an 
antibody that does not interfere with or promote the bio-
logical activity of a brain tumor stem cell marker protein and 
may instead function to inhibit tumor growth by, for 
of the embodiment of the composition, making an initial 65 
assessment of a sample of the composition ( control sample), 
subjecting a sample of the composition to conditions of 
example, antibody internalization and/or recognition by the 
immune system. 
In some embodiments, the targeting module may include 
a lectin or another ligand specific to the transferrin receptor. 
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A brain tumor targeting module may further e a ligand to one 
of any number of cell surface receptors or antigens, such as 
RGD. 
12 
nucleic acid molecule. In another embodiment, the siRNA 
comprises a single stranded polynucleotide having one or 
more loop structures and a stem comprising self comple-
mentary sense and antisense regions, wherein the antisense Further examples of the targeting module is a chemical 
molecule, a small drug molecule or a chromophore mol-
ecule, or a protein molecule, or a lectin that are covalently 
joined to polymalic acid in constructing the conjugation with 
the RNA nanoparticle. 
The term "folate" as used herein can comprise, for 
example, a genus of well-defined B-vitamin compounds, 
including but not limited to, 5-methyltetrahydro folate, 
5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, 
folic acid and other folate compounds. Since folate is an 
essential component required during DNA replication and 
methylation in highly proliferating cells, many cancer cells, 
such as those of the brain, ovary, lung, breast, kidney, 
endometrium, colon and bone marrow, over-express FRs to 
increase folate uptake (19). Folic acid (FA), a synthetic 
oxidized form of folate, has been widely used as a ligand in 
various cancer targeting materials (20). 
5 region comprises a sequence complementary to a region of 
a target nucleic acid molecule, and wherein the polynucle-
otide can be processed either in vivo or in vitro to generate 
an active siRNA capable of mediating RNAi. As used 
herein, siRNA molecules need not be limited to those 
10 molecules containing only RNA, but further encompass 
chemically modified nucleotides and non-nucleotides. 
In some embodiments, the siRNA molecule of the pres-
ently disclosed subject matter is a siRNA molecule that 
binds to a single stranded RNA molecule, which is a 
15 messenger RNA (mRNA) that encodes at least part of a 
peptide or protein whose activity promotes tumorigenesis, 
angiogenesis, or cell proliferation in the brain or spinal cord 
of a manimal, or which is a micro-RNA (miRNA) whose 
activity promotes tumorigenesis, angiogenesis, or cell pro-
20 liferation in the brain or spinal cord of a mammal. In some 
embodiment of the present disclosure, to interfere oncogenic 
coding genes to regress brain tumor growth, the RNA 
nano structure molecule silence oncogenes, including but not 
limited to, RAS, cMET, HER2. MDM2, PIK3CA, AKT, and 
In some embodiments, the presently disclosed subject 
matter provides a bioactive agent includes a drug, a fluo-
rescent dye, a chemical, or a combination thereof. In some 
embodiments, the bioactive agent includes an imaging mod-
ule. Non-limiting examples of the imaging module is fluo-
rescent dye, including a non-limiting example Alexa647. In 
some embodiments, the bioactive agent is coupled to the 
RNA nanostructure molecule. In some embodiments, the 
bioactive agent is a therapeutic agent. In some embodiments, 
the bioactive agent includes a siRNA, a miRNA, an anti- 30 
miRNA, a ribozyme RNA, an antisense RNA, or a combi-
nation thereof. In some embodiments, the bioactive agent is 
directed to a brain tumor marker. Non-limiting examples of 
the bioactive agent include siRNA sequence and microRNA 
sequence. 
25 CDK4. 
The phrase "brain tumor marker" as used herein refers to 
genes or gene products ( e.g., RNA molecules or proteins) 
which are characteristic of some or all of the cells in brain 
cancer. A brain cancer marker with diagnostic value can be 
a gene or gene product expressed in normal, non-cancerous 
cells, but is characteristic of a type or classification of cancer 
by, for example, its over-expression or under-expression as 
compared to its expression in normal, non-cancerous cells. 
A brain tumor marker with prognostic value is a gene or 
RNA interference (RNAi) is a polynucleotide sequence-
specific, post-transcriptional gene silencing mechanism 
effected by double-stranded RNA that results in degradation 
35 gene product for which the over-expression or under-ex-
pression confers predictive information about the future 
aggressiveness of a cancer and/or its response to therapy at 
the time of diagnosis. In a cancer sample, the patterns of 
expression of diagnostic and prognostic cancer markers of a specific messenger RNA (mRNA), thereby reducing the 
expression of a desired target polypeptide encoded by the 
mRNA (see, e.g., WO 99/32619; WO 01/75164; U.S. Pat. 
No. 6,506,559; Fire et al., Nature 391:806-11 (1998): Sharp, 
Genes Dev. 13:139-41 (1999); Elbashir et al. Nature 411: 
494-98 (2001); Harborth et al., J. Cell Sci. 114:4557-65 
(2001)). RNAi is mediated by double-stranded polynucle- 45 
otides as also described hereinbelow, for example, double-
stranded RNA (dsRNA), having sequences that correspond 
40 allow one to accurately identify and determine the future 
course of the disease, respectively. Non-limiting examples 
of brain tumor biomarkers are described in WO2007069882 
(herein incorporated by reference in its entirety). 
to exonic sequences encoding portions of the polypeptides 
for which expression is compromised. 
The terms "small interfering RNA", "short interfering 50 
RNA", "small hairpin RNA", "siRNA", and shRNA are 
used interchangeably and refer to any nucleic acid molecule 
capable of mediating RNA interference (RNAi) or gene 
silencing. See e.g., Bass, Nature 411:428-429, 2001; 
Elbashir et al., Nature 411:494-498, 2001a; and PCT Inter- 55 
national Publication Nos. WO 00/44895, WO 01/36646, 
WO 99/32619, WO 00/01846, WO 01/29058, WO 
99/07409, and WO 00/44914. In one embodiment, the 
siRNA comprises a double stranded polynucleotide mol-
ecule comprising complementary sense and antisense 60 
regions, wherein the antisense region comprises a sequence 
complementary to a region of a target nucleic acid molecule 
(for example, a nucleic acid molecule encoding BRCAAl). 
In another embodiment, the siRNA comprises a single 
stranded polynucleotide having self-complementary sense 65 
and antisense regions, wherein the antisense region com-
prises a sequence complementary to a region of a target 
In one embodiment, the siRNA molecule binds to an 
mRNA that encodes at least part of a peptide or protein 
whose activity promotes tumorigenesis, angiogenesis, or 
cell proliferation, or a combination thereof, in the brain or 
spinal cord of a manimal. Such may be the case when the 
mRNA molecule encodes a protein in a pro-tumorigenic 
pathway, pro-angiogenesis pathway, pro-cell proliferation 
pathway, or anti-apoptotic pathway. For example, the pro-
tein can be a VEGF pathway protein, EGFR pathway 
protein, MGMT pathway protein, RAF pathway protein. 
MMP pathway protein, mTOR pathway protein, TGF~ 
pathway protein, or Cox-2 pathway protein. In one embodi-
ment, the protein is one of the following, including but not 
limited to, VEGF, EGFR, PDK, AKT, AGT, RAFI, RAS, 
MAPK, ERK, MGMT, MMP-2, MMP-9, PDGF, PDGFR, 
IGF-I, HGF, mTOR, Cox-2, or TGF~l. In another embodi-
ment, the protein is VEGF. EGFR. MGMT, MMP-2, MMP-
9, or PDGF. In still another embodiment, the protein is 
RAFI, mTOR, Cox-2, or TGF~l. 
In some embodiments, the present disclosure provides 
that the bioactive agent is a microRNA sequence. As used 
herein, the term "Micro RN As (miRNAs )" as used herein are 
single-stranded, or double stranded non-coding RNAs, at 
least about 6 nucleotide in length that can regulate gene 
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expression at the post-transcriptional level by either degrad-
ing their target mRNAs or inhibiting their translation (See, 
e.g. Bartel, D. P., (2004), Cell, 116, 281-297; Liang Z., et al., 
(2013), J Genet. Genomics, 40, 141-142). MiRNAs play 
important roles in regulating cell cycle, proliferation, dif- 5 
ferentiation, metabolism, and apoptosis. A compendium of 
microRNA and respective microRNA binding sequences is 
available at the miRNA registry. (See, e.g., Griffiths-Jones et 
al. (2006) Nucl. Acids Res. 34:D140-Dl44, 
US20140045709, herein incorporate by reference in their 10 
entireties.) In particular embodiments, the microRNA and 
microRNA binding sequence employed in the present dis-
closure are associated with a disease or condition, wherein 
an antagonist or agonist to the microRNA would be useful 
in preventing or treating the disease or condition. Dysregu- 15 
lation of miRNAs has been implicated in tumor initiation, 
progression, and metastasis in several cancer types (See, 
Carlin G. A., et al., Nat. Rev. Cancer 2006, 6, 857-866; Di 
L. G., et al., Annu. Rev. Pathol. 2014, 9, 287-314; Garzon, 
R. et al., Annu. Rev. Med. 2009, 60, 167-179; Iorio, M. V., 20 
et al., Cancer Res 2005, 65, 7065-7070; Croce, C. M., et al., 
Cell 2005, 122, 6-7.). MiRNAs hold great potentials for 
cancer therapy particularly because one miRNA can regulate 
a broad set of target genes efficiently and simultaneously, 
and can therefore address the heterogeneous nature of can- 25 
cer. Naturally occurring miRNA further displays reduced 
immune response and low toxicity. Both anti-miRNAs to 
knockdown oncogenic miRNAs and mimics of miRNAs to 
upregulate endogenous miRNAs have been developed as 
therapeutic strategies to achieve tumor regression (Henry, J., 30 
et al. Pharm Res 2011, 28, 3030-3042). However, the major 
limiting factor is the ability to specifically deliver these 
therapeutic modules to affected cells and tissues. Nanotech-
nology holds great promise in this regard and several 
nanoplatforms have been pursued, but effective strategies to 35 
inhibit tumor progression are still lacking (Grodzinski, P.; 
Torchilin, V.; (Editors) Adv. Drug Delivery Rev.: Cancer 
Nanotechnology; Volume 66 ed.; Elsevier: 2014.). 
In some embodiments, the microRNA or anti-miRNA 
sequence is at least about 3 nucleotide in length. In some 40 
embodiments, the miRNA molecule has a length of at least 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 
21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more. IN 
some embodiments, an anti-miRNA or an antagomir of a 
miRNAmolecule is at least about 6 nucleotides in length. In 45 
some embodiments, the antagomir of a miRNA molecule 
has a length of at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 
29, 30 nucleotides or more. 
In some embodiments, to interfere oncogenic miRNA to 50 
regress brain tumor growth, the RNA nanostructure mol-
ecule contains anti-miRNA that silences oncogenic miR-
NAs, including but not limited to, miR-9, miR-l0b, miR-21, 
miR-17, and miR-26. In some embodiments, to rescue 
down-regulated tumor suppressive miRNAs, RNA nano- 55 
structure introduces includes tumor suppressive miRNAs, 
including but not limited to, let-7a, miR-l0b, miR-25, 
miR-34a, miR-124, miR-145, and miR-181b. MiRNA 
sequences are listed below: 
60 
miR-9, (SEQ ID NO, 8) 

















(SEQ ID NO, 10) 
(SEQ ID NO, 11) 
( SEQ ID NO, 12) 
( SEQ ID NO, 13) 
( SEQ ID NO, 14) 
(SEQ ID NO, 15) 
(SEQ ID NO, 16) 
In some embodiments, the microRNA includes a locked 
nucleic acid (LNA) sequence. In some embodiments, the 
microRNAis a LNA-anti-miR21 sequence 5'-+G+A+T+A+ 
A+G+C+ T CTC CCG GCC GCC ATG GCC GCG GGA T-3' 
(SEQ ID NO: 7) (underlined sequence is 8-mer anti-miR21 
LNA, and "+" denotes LNA sequence). In some embodi-
ments, the RNA nanostructure contains a strand 
LNAl 7 _sphl: 5'-+A+G+C+A+C+ T + T + TCTCCCGGC-
CGCCATGGCCGCGGGAT-3' (SEQ ID NO: 17) ("+" 
denotes LNA sequence.) In another embodiment, the RNA 
nanostructure contains a strand of LNA19a_sphl: 5'-+A+ 
T+T+T+G+C+A+CCTCCCGGCCGCCATGGC-
CGCGGGAT-3' (SEQ ID NO: 18) ("+" denotes LNA 
sequence.). 
In some embodiments, the present disclosure provides 
inhibitors of miRNAs (e.g., anti-miR-21). Compositions 
comprising such inhibitors and methods for inhibiting miR-
21 using such inhibitors are also disclosed herein. Any 
miRNA inhibitor may be used alone, or with other miRNA 
inhibitor(s) known in the art. In some embodiments, the 
miRNA inhibitor comprises an antisense molecule. In some 
embodiments, the antisense molecule could be a single or a 
double stranded sequence. Examples of antisense molecule 
include, but are not limited to, siRNAs, triple-helix-forming 
agents, ribozymes, RNAi, synthetic peptide nucleic acids 
(PNAs), antigenes (agRNAs), LNA/DNAcopolymers, small 
molecule chemical compounds, and antisense oligonucle-
otides. 
Further provided, in some embodiments of the presently 
disclosed subject matter, is a nucleic acid composition. The 
composition includes a therapeutically effective amount of 
the artificial RNA nanostructure molecule as disclosed 
above. In some embodiments, the composition includes a 
pharmaceutically acceptable carrier. 
Still further, the presently disclosed subject matter, in 
some embodiments, provides a nanoparticle delivery sys-
tem. The delivery system includes the artificial RNA nano-
structure molecule as disclosed above. In some embodi-
ments, the nanoparticle delivery system further includes a 
pharmaceutically acceptable carrier. 
In another aspect, the presently disclosed subject matter 
provides, in some embodiments, a method of treating a brain 
tumor in a subject having or at risk of developing a brain 
tumor. The method includes administering to the subject a 
therapeutically effective amount of a composition compris-
miR-l0b, 
5'-UACCCUGUAGAACCGAAUUUGUG-3' 
(SEQ ID NO, 9) 
65 ing an artificial RNA nanostructure molecule as disclosed 
above and herein. In some embodiments, the composition 
includes a pharmaceutically acceptable carrier. 
US 10,584,144 B2 
15 
Further, in some embodiments, the present disclosure 
provides a method of preventing brain tumor recurrence a 
subject having or at risk of having brain tumor recurrence. 
The method includes administering to the subject a thera-
peutically effective amount of a composition comprising an 
artificial RNA nanostructure molecule as disclosed above 
and herein. In some embodiments, the composition includes 
a pharmaceutically acceptable carrier. 
Brain tumors are a very serious and are among the most 
difficult to treat, with a very short survival in patients, 
despite administration of the optimal treatment available. 
The very unique biological environment of the brain, as 
separated by the blood-cerebrospinal fluid barrier (BCFB), 
significantly contributes to a range of site-specific cancers in 
this organ that require alternative treatment than those 
cancers of the remaining human body. Treatment consists 
primarily of surgical removal and radiation therapy; chemo-
therapy is also used, but the range of suitable chemothera-
peutic agents is limited, perhaps because most therapeutic 
agents do not penetrate the blood-brain barrier adequately to 
treat brain tumors. Using known chemotherapeutics along 
with surgery and radiation rarely extends survival much 
beyond that produced by surgery and radiation alone. Thus 
improved therapeutic options are needed for brain tumors. 
In some embodiments, the brain tumor is a glioma. 
16 
prises 2'Fluoro, 2'Amine, 2'O-Methyl, or a combination 
thereof. In some embodiments, the motif is a three-branched 
RNA junction motif. An non-limiting example of the three-
branched RNA junction motif comprises a packaging RNA 
5 (pRNA) three-way junction (3WJ) motif. In some embodi-
ments, the diameter of the molecule is at least about 40 nm 
or less. In some embodiments, the molecule has a zeta 
potential ranging from about -50 m V to about 50 m V. In 
some embodiments, the multiple branched RNA includes a 
10 nucleotide 5'-UUG CCA UGU GUA UGU GGG AUC CCG 
CGG CCA UGG CGG CCG GGA G-3' (SEQ ID NO: 6). In 
another embodiment, the multiple branched RNA comprises 
sequence 5'-GATAAGCT CTC CCG GCC GCC ATG GCC 
GCG GGA T-3' (SEQ ID NO: 7). In some embodiments, a 
15 branch of the three-branched RNA junction motif includes at 
least one ofana3WJ RNA module (SEQ ID NO: 1); a b3WJ 
RNA module (SEQ ID NO: 2); or a c3WJ RNA module 
(SEQ ID NO: 3). 
In some embodiments, the brain tumor targeting module 
20 in the method(s) of the presently disclosed subject matter 
includes a ligand that binds to at least one brain tumor cell 
surface marker. In some embodiments, the ligand binds to a 
folate receptor, an EGFR, a transferrin receptor, an RGD, or 
a combination thereof. In some embodiments, the ligand 
25 comprises an aptamer. In some embodiments, the targeting 
module comprises a folate. Non-limiting examples offolate 
include folic acid, 5-methyltetrahydro folate, 5-formyltetra-
hydrofolate, dihydrofolate, tetrahydrofolate, or other folate 
Gliomas are a common type of brain tumor. They arise from 
the supportive neuronal tissue comprised of glial cells 
(hence the name glioma), which maintain the position and 
function of neurons. In some embodiments, gliomas are 
classified according to the type of glial cells they resemble: 30 
astrocytomas (including glioblastomas) resemble star-
shaped astrocyte glial cells, oligodendrogliomas resemble 
oligodendrocyte glial cells; and ependymomas resemble 
ependymal glial cells that form the lining of fluid cavities in 
the brain. In some embodiments, a tumor may contain a 
mixture of these cell types, and would be referred to as a 
mixed glioma. 
compounds. 
In some embodiments, the therapeutic agents in the meth-
od(s) of the presently disclosed subject matter includes a 
drug, a fluorescent dye, a chemical, or a combination 
thereof. Further, the therapeutic agent includes a siRNA, a 
miRNA, an anti-miRNA, a ribozyme RNA, an antisense 
35 RNA, or a combination thereof. In some embodiments, the 
therapeutic agent is directed to a brain tumor marker. In 
some embodiments, the therapeutic agent is a siRNA 
sequence, or a microRNA sequence. In some embodiments, 
the microRNA sequence is at least 6 nucleotide in length. 
As disclosed herein, in some embodiments, the brain 
tumor is a glioblastoma. Glioblastomas is the most common 
primary brain tumors in adults and are also one of the most 
deadly cancers (1 ). The median survival of patients with 
glioblastoma is less than 15 months. The poor prognosis is 
primarily due to tumor recurrence, which is thought to 
originate from a subset of cancer stem cells that survive the 
primary treatments. Recent studies suggested that glioblas-
toma stem cell survived the therapeutic stresses and become 
more aggressive when they recur, developing resistance to 
the primary chemotherapy. In some embodiment, the pres-
ently disclosed subject matter provides a method of admin-
istering the RNA nanostructure composition as disclosed 
herein to both brain tumor cells and glioblastoma stem cells 
to treat the primary brain tumor and prevent tumor recur-
rence. 
40 Non-limiting example of the microRNA is a locked nucleic 
acid (LNA) sequence. An example of the LNA sequence is 
is a LNA-miR21 sequence as described herein. In some 
embodiments, the siRNA binds to a mRNA sequence of a 
gene that promotes tumorigenesis, angiogenesis, cell prolif-
45 eration, or a combination thereof, in the brain or spinal cord. 
In some embodiments, the siRNA binds to a mRNA mol-
ecule that encodes a protein including pro-tumorigenic path-
way proteins, pro-angiogenesis pathway proteins, pro-cell 
proliferation pathway proteins, anti-apoptotic pathway pro-
50 teins, or a combination thereof. In some embodiments, the 
mRNA molecule encodes a protein including VEGF path-
way proteins, EGFR pathway proteins, MGMT pathway 
proteins, Rafi pathway proteins, MMP pathway proteins, 
mTOR pathway proteins, TGF~ pathway proteins, or Cox-2 In some embodiments, the method(s) as disclosed herein 
includes administering to the subject a therapeutically effec-
tive amount a composition. The composition includes an 
artificial RNA nanostructure molecule, wherein the mol-
ecule includes a multiple branched RNA junction motif 
comprising at least one RNA oligonucleotide, a brain tumor 
targeting module coupled to an RNA junction motif, and at 60 
least one therapeutic agent coupled to the RNA junction 
motif. In some embodiments, the composition further 
includes a pharmaceutically acceptable carrier. In some 
embodiments, the bioactive agent comprises a therapeutic 
agent. In some embodiments, the RNA oligonucleotide 
comprises at least one chemical modification at the 2' 
position. Non-limiting examples of the modification com-
55 pathway proteins, or a combination thereof. In some 
embodiments, the protein includes VEGF, EGFR, POK, 
AKT, AGT, RAF, RAS, MAPK, ERK, MGMT, MMP-2, 
MMP-9, PDGF, PDGFR, IGF-I, HGF, mTOR, Cox-2 or 
TGF~l. 
Further, in some embodiments of the methods, the present 
subject matter relates to a method to target and deliver 
therapeutic siRNA to brain tumors using FA-conjugated 
pRNA-3WJ RNP. First, intracranial tumor xenograft models 
in mice was established and then systemically administered 
65 RNPs through the tail vein. Based on fluorescence imaging, 
It is demonstrated that the pRNA-3WJ RNP efficiently 
targeted and internalized into brain tumor cells through 
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FR-mediated endocytosis with little or no accumulation in 
adjacent healthy brain cells. Gene silencing by the RNPs 
was also demonstrated within the luciferase gene expressing 
brain tumors. More importantly, pRNA-3WJ RNPs were 
also capable of targeting brain tumor stem cells derived from 5 
a human patient. The data demonstrate that artificially 
engineered RNPs can specifically target brain tumor cells, 
including glioblastoma stem cells, and deliver functional 
siRNA and therapeutic microRNAs (miRNAs) (21). 
of administration; the route of administration; the rate of 
excretion of the specific compound employed; the duration 
of the treatment; drugs used in combination or coincidental 
with the specific compound employed and like factors well 
known in the medical arts. For example, it is well within the 
skill of the art to start doses of a compound at levels lower 
than those required to achieve the desired therapeutic effect 
and to gradually increase the dosage until the desired effect 
is achieved. If desired, the effective daily dose can be 
divided into multiple doses for purposes of administration. 
The term "treatment" and "prophylaxis" as used herein is 10 
to be considered in its broadest context. The term "treat-
Consequently, single dose compositions can contain such 
amounts or submultiples thereof to make up the daily dose. 
The dosage can be adjusted by the individual physician in 
ment" does not necessarily imply that a host is treated until 
total recovery. Similarly, "prophylaxis" does not necessarily 
mean that the subject will not eventually contract a disease 
condition. Accordingly, treatment and prophylaxis include 
amelioration of the symptoms of a particular condition or 
preventing or otherwise reducing the risk of developing a 
particular condition. The term "prophylaxis" may be con-
sidered as reducing the severity of onset of a particular 
condition. "Treatment" may also reduce the severity of an 
existing condition. 
The term "pharmaceutically acceptable carrier" as used 
herein refers to a diluent, adjuvant, excipient, or vehicle with 
which a heterodimeric probe of the disclosure is adminis-
tered and which is approved by a regulatory agency of the 
federal or a state govermnent or listed in the U.S. Pharma-
copeia or other generally recognized pharmacopeia for use 
in animals, and more particularly in humans. Such pharma-
ceutical carriers can be liquids, such as water and oils, 
including those of petroleum, animal, vegetable, or synthetic 
origin, such as peanut oil, soybean oil, mineral oil, sesame 
oil, and the like. The pharmaceutical carriers can be saline, 
gum acacia, gelatin, starch paste, talc, keratin, colloidal 
silica, urea, and the like. When administered to a patient, the 
heterodimeric probe and pharmaceutically acceptable carri-
ers can be sterile. Water is a useful carrier when the 
heterodimeric probe is administered intravenously. Saline 
solutions and aqueous dextrose and glycerol solutions can 
also be employed as liquid carriers, particularly for inject-
able solutions. Suitable pharmaceutical carriers also include 
excipients such as glucose, lactose, sucrose, glycerol monos-
tearate, sodium chloride, glycerol, propylene, glycol, water, 
ethanol, and the like. The present compositions, if desired, 
can also contain minor amounts of wetting or emulsifying 
agents, or pH buffering agents. The present compositions 
advantageously may take the form of solutions, emulsion, 
sustained release formulations, or any other form suitable for 
use. 
The term "therapeutically effective amount," as used 
herein, refers to the amount of a composition containing 
administered to a patient already suffering from a disease, 
condition, or disorder, sufficient to cure or at least partially 
arrest, or relieve to some extent one or more of the symp-
toms of the disease, disorder, or condition being treated. The 
effectiveness of such compositions depend upon conditions 
including, but not limited to, the severity and course of the 
disease, disorder, or condition, previous therapy, the 
patient's health status and response to the drugs, and the 
judgment of the treating physician. By way of example only, 
therapeutically effective amounts may be determined by 
routine experimentation, including but not limited to a dose 
escalation clinical trial. 
The specific therapeutically effective dose level for any 
particular patient will depend upon a variety of factors 
including the disorder being treated and the severity of the 
disorder; the specific composition employed; the age, body 
weight, general health, sex and diet of the patient; the time 
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the event of any contraindications. Dosage can vary, and can 
be administered in one or more dose administrations daily, 
for one or several days. Guidance can be found in the 
literature for appropriate dosages for given classes of phar-
maceutical products. In further various aspects, a prepara-
20 tion can be administered in a "prophylactically effective 
amount"; that is, an amount effective for prevention of a 
disease or condition. 
As used herein, the term "subject" refers to a target of 
administration of the pharmaceutical composition. The sub-
25 ject of the herein disclosed methods can be a vertebrate, such 
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, 
the subject of the herein disclosed methods can be a human 
or non-human. Thus, veterinary therapeutic uses are pro-
vided in accordance with the presently disclosed subject 
30 matter. As such, the presently disclosed subject matter 
provides for administration to mammals such as humans and 
non-human primates, as well as those mammals of impor-
tance due to being endangered, such as Siberian tigers; of 
economic importance, such as animals raised on farms for 
35 consumption by humans; and/or animals of social impor-
tance to humans, such as animals kept as pets or in zoos. 
Examples of such animals include but are not limited to: 
carnivores such as cats and dogs; swine, including pigs, 
hogs, and wild boars; ruminants and/or ungulates such as 
40 cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; 
rabbits, guinea pigs, and rodents. Also provided is the 
treatment of birds, including the treatment of those kinds of 
birds that are endangered and/or kept in zoos, as well as 
fowl, and more particularly domesticated fowl, i.e., poultry, 
45 such as turkeys, chickens, ducks, geese, guinea fowl, and the 
like, as they are also of economic importance to humans. 
Thus, also provided is the treatment of livestock, including, 
but not limited to, domesticated swine, ruminants, ungu-
lates, horses (including race horses), poultry, and the like. 
50 The term does not denote a particular age or sex. 
Suitable methods for administering to a subject an effec-
tive amount of the composition in accordance with the 
methods of the present invention include but are not limited 
to systemic administration, parenteral administration (in-
55 eluding intravascular, intramuscular, intraarterial adminis-
tration), oral delivery, buccal delivery, subcutaneous admin-
istration, inhalation, intratracheal installation, surgical 
implantation, transdermal delivery, local injection, and 
hyper-velocity injection/bombardment. Where applicable, 
60 continuous infusion can enhance drug accumulation at a 
target site (see, e.g., U.S. Pat. No. 6,180,082). 
The particular mode of drug administration used in accor-
dance with the methods of the present invention depends on 
various factors, including but not limited to the vector and/or 
65 drug carrier employed, the severity of the condition to be 
treated, and mechanisms for metabolism or removal of the 
drug following administration. 
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The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 5 
related to the presently disclosed subject matter. 
EXAMPLES 
20 
and computational prediction implies that each protruded 
branch of FA-pRNA-3WJ-si(luc) RNP was avoided from 
averaging three dimensions due to rapid motion of nano-
particles in solution. Another factor that needs to be 
addressed for successful systemic in vivo application of 
nanoparticles is freedom from aggregation to avoid rapid 
clearance from the body and diminished specific interaction 
between the conjugated ligand and cellular target receptors. 
Aggregation depends largely on the surface charge of nano-
Example 1 10 particles and the surface of RNA is indeed highly charged. 
Glioblastoma is one of the most deadly cancers. Systemic 
siRNA administration to treat glioblastoma patients requires 
Aggregation will also change the surface charge propor-
tional to the extent of size increase. To determine the 
aggregation extent, FA-pRNA-3WJ-si(luc) RNP was sub-
jected to zeta potential analysis to measure the particle a robust and efficient delivery platform without immunoge-
nicity. This example report the application of RNA nano-
technology based on pRNA 3-way-junction (3WJ) of bac-
teriophage phi29 for glioblastoma targeting. Multivalent 
folate (FA)-conjugated RNAnanoparticles were constructed 
to harbor siRNA. The resulted FA-pRNA-3WJ RNA nano-
particle (RNP) specifically targeted and entered human 
malignant glioblastoma cells in vitro and intracranial glio-
blastoma xenografts in vivo. Systemically injected 
FA-pRNA-3WJ RNPs successfully targeted and delivered 
siRNA into brain tumor cells in mice, and efficiently reduced 
luciferase reporter gene expression ( 4-fold lower than con-
trol). The FA-pRNA-3WJ RNA nanoparticles were also 
demonstrated to target both human patient-derived glioblas-
toma stem cells, which are thought to be responsible for 
tumor initiation, drug resistance and deadly recurrence, and 
the derived brain tumor in mouse model without accumu-
lation in adjacent normal brain cells, nor other major internal 
organs. The results of this study may promise a successful 
clinical application of pRNA-3WJ RNP for specific delivery 
15 surface charge. Zeta potential of FA-pRNA-3WJ-si(luc) 
RNP in PBS solution was measured as a single peak at 
-15.8±5.6 mV (FIG. lD), indicating that most FA-pRNA-
3 WJ-si(luc) RNP exist as a single form without aggregation. 
These physical properties favor the FA-pRNA-3WJ-si(luc) 
20 RNP for systemic in vivo application. 
Human glioblastoma cells are known to overexpress FR, 
while normal brain cells show no FR expression (17-19). To 
determine the specific recognition and binding capability of 
FA-pRNA-3WJ-si(luc) RNP towards human glioblastoma 
25 cells, firstly association of FA-Alexa647-pRNA-3WJ with 
U87EGFRvIII cell was tested in vitro in comparison to 
FA-free control RNP (Alexa647-pRNA-3WJ). Flow cytom-
etry analysis showed a higher association of FA-Alexa647-
pRNA-3WJ with U87EGFRvIII cells (63.1±4.5%) than that 
of therapeutics such as siRNA, microRNA and/or chemo-
therapeutic drugs into glioblastoma cells without inflicting 
collateral damage to healthy tissues. 
30 of Alexa647-pRNA-3WJ (40.3±3.7%) (student t-test, 
p<0.001, n=4) (FIG. 2A). When FRs ofU87EGFRvIII cells 
were pre-masked by incubating with 1 mM free-folate for 1 
hr of culture before the RNP binding, the association 
between FA-Alexa647-pRNA-3WJ and U87EGFRvIII cells 
Results and Discussion 
35 was decreased to an extent similar to the negative control 
Alexa647-pRNA-3WJ (FIG. 5), indicating that the associa-
tion between FA-Alexa647-pRNA-3WJ and U87EGFRvIII 
cells was FR dependent. The FR-mediated specific binding 
of FA-Alexa647-pRNA-3WJ to U87EGFRvIII cells was 
This study was to assess application ofpRNA-3WJ RNP 
for systemic delivery of therapeutic RNA, such as siRNA 
and miRNA, into brain tumors in a mouse model system. For 
targeted delivery of siRNA into brain tumors, a multifunc-
tional RNP was constructed, as previously described (7,12, 
13,22), using a scaffold based on pRNA sequences of phi29 
bacteriophage with slight modifications (see Materials and 
Methods). Three RNA modules individually transcribed in 45 
vitro or synthesized chemically were mixed at equal molar 
ratio and formed three-branched RNP via one-step self-
assembly. Each RNA module was designed to carry a 
functional moiety: 1) FA as the FR targeting ligand; 2) 
fluorophore Alexa647 as the imaging agent; and 3) 50 
luciferase siRNA as the gene silencing functional moiety or 
scrambled RNA as a negative control (FIG. lA) (7,12,13, 
22). The resulting RNP was named FA-pRNA-3WJ-si(luc) 
RNP. Observation of the self-assembled FA-pRNA-3WJ-si 
(luc) RNP under atomic force microscopy (AFM) revealed 55 
the formation of homogeneous three-branched architectures 
with 3WJ core in the center (FIG. lB), confirming the 
previous reports that modifications on each RNA module did 
not abrogate the shape-controlled self-assembly to retain the 
pRNA-3WJ core structure essential for homogeneous uni- 60 
formed RNP formation. Dynamic light scattering (DLS) 
determined average hydrodynamic diameters ofFA-pRNA-
3WJ-si(luc) RNP to be 5.2±1.2 nm (FIG. lC), which was 
smaller than the predicted size (10x4x2 nm) calculated by 
RNA folding software based on expected duplex helix 65 
parameters and base pair lengths of the three individual 
RNA modules. The discrepancy between DLS measurement 
40 further confirmed by visualizing the Alexa647 signal from 
surface-cultured U87EGFRvIII cells treated with FA-Al-
exa647-pRNA-3WJ RNP under confocal fluorescence 
microscope. Higher fluorescence intensity of Alexa647 dye 
was observed from U87EGFRvIII cells treated with FA-Al-
exa647-pRNA-3WJ than those with control RNP (Al-
exa647-pRNA-3WJ) (FIG. 2B). Again, the FA-dependent 
association of FA-Alexa647-pRNA-3WJ RNP was abol-
ished by pre-treatment of U87EGFRvIII cells with 1 mM 
free folate in culture medium (FIG. 2B). The FR-mediated 
specific association between FA-Alexa647-pRNA-3WJ 
RNP and human glioblastoma cell was also observed with 
other glioblastoma cell lines including T98G (FIG. 6). Taken 
together, FA-conjugated pRNA-3WJ RNP has the capability 
to recognize and bind to human brain tumor cells through 
FR. 
Next, we tested whether FA-pRNA-3WJ RNP can spe-
cifically target tumor cells in vivo using an orthotropic 
mouse model of glioblastoma. On the 14th day post 
U87EGFRvIII cell implantation into nude mouse brain, 
intracranial tumor growth in mice was determined by MRI 
(FIG. 2C, top) and randomly separated into three groups for 
injection of PBS, Alexa647-pRNA-3WJ as two negative 
controls and FA-Alexa647-pRNA-3WJ as experimental. 
Each group of mice (n=4) was injected via tail vein (1 mg/kg 
of RNP in 100 µL of PBS). Fifteen hours post injection, the 
mice brains were dissected and subjected to fluorescence 
imaging to detect the Alexa647 signal from RNP. A higher 
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fluorescence signal of Alexa647 was observed in the brains averaged luciferase activity over tumor volumes from the 
mice treated with FA-pRNA-3WJ-si(Luc) (0.255±0.040 
Luminescence Radiance [p/s/cm2/sr]/tumor volume [mm3], 
s.e.m.) was significantly lower compared to the control mice 
group treated with FA-pRNA-3WJ-si(Scrm) (1.000±0.410 
Luminescence Radiance [p/s/cm2/sr]/tumor volume [mm3], 
s.e.m.) (p=0.015, n=5) (FIG. 4E). These data strongly indi-
cated that FA-pRNA-3WJ RNP not only specifically tar-
geted glioblastoma cells, but also successfully internalized 
into the cells and delivered the cargo siRNA. The delivered 
siRNA, more importantly, remained functionally intact for 
the whole time of systemic delivery, confirming both sta-
bility and therapeutic efficacy of the FA-pRNA-3WJ RNPs. 
The data successfully demonstrated the therapeutic usability 
as a siRNA delivery system for glioblastoma treatment. 
In clinical settings, glioblastomas are notorious for their 
frequent recurrence with increased aggressiveness after ini-
tial therapy, resulting in poor survival rates. It has been 
hypothesized that glioblastoma stem cells tend to survive the 
of mice injected with FA-Alexa647-pRNA-3WJ than that in 
the mice brains injected with control RNP (Alexa647-
pRNA-3WJ) (FIG. 2C). ANOVA analysis on the fluores-
cence intensity from each group (n=4) normalized by their 5 
tumor volumes (Alexa647 intensity/tumor volume) con-
firmed the significant increase in average fluorescence inten-
sity in the mouse brains treated with FA-Alexa647-pRNA-
3WJ (2.052±0.416, s.e.m.) compared to Alexa647-pRNA-
3WJ (1.014±0.279, s.e.m.) (p=0.019) with respect to PBS 10 
(1.000±0.298, s.e.m.) (FIG. 2D). The brain tumor region 
was frozen sectioned (10 µm thick) and further examined 
under a fluorescence confocal microscope. It revealed that 
FA-Alexa647-pRNA-3WJ RNP was mostly associated with 
counterstained brain tumor cells (Supplementary FIG. 7). 15 
These in vivo data strongly indicated that systemically 
injected FA-Alexa647-pRNA-3WJ RNP can travel to brain 
tissue, and successfully recognize and bind human glioblas-
toma cells through FA-FR interaction, rather than randomly 
distribute throughout the entire brain tissues. 20 initial treatment and induce tumor recurrence, meaning that 
any therapeutic strategy lacking the ability to kill glioblas-
toma stem cells would not prevent recurrences (23). The 
potential of FA-pRNA-3WJ RNPs to target glioblastoma 
After binding to target glioblastoma cells, RNP needs to 
internalize to deliver its cargo, siRNA, for successful target 
gene silencing, which is the most critical property for any 
nanoparticle to claim its therapeutic application. In order to 
test whether siRNA-loaded FA-3WJ RNP can silence the 25 
stem cells and their derived tumor cells was investigated. We 
used human glioblastoma patient-derived primary neuro-
sphere cells, named "1123", which has been shown to target gene in glioblastoma cells in mouse brain after sys-
temic administration, we set up a luciferase-based gene 
expression reporter system by implanting luciferase gene-
expressing U87EGFRvIII cells (U87EGFRvIII-Luc) in 
mouse brain. For a preliminary in vitro test, U87EGFRvIII-
Luc cells were incubated for 72 hrs in culture medium 
containing a range between O and 400 nM of FA-pRNA-
3WJ-si(Luc) or scrambled RNA-conjugated control 
FA-pRNA-3WJ-si(Scrm) RNPs without any transfection 
agent. After 72 hrs, FA-pRNA-3WJ-si(Luc) clearly reduced 
luciferase activity in a concentration dependent manner. At 
400 nM, average luciferase activity in U87EGFRvIII-Luc 
cells incubated with FA-pRNA-3WJ-si(Luc) was decreased 
about five folds (0.214±0.210, s.e.m.) with respect to O nM. 
However, FA-pRNA-3WJ-si(Scrm) did not significantly 
reduce luciferase activity in the cells (0.876±0.056, s.e.m.) 
compared to O nM. The difference of luciferase activity at 
400 nM between FA-pRNA-3WJ-si(Luc) and FA-pRNA-
3WJ-si(Scrm) was statistically significant (p=0.006) (FIG. 
3A). For in vivo test, intracranial tumor in mice was induced 
by implanting U87EGFRvIII-Luc cells. Bioluminescence 
signal measured from the resulted brain tumor is expected to 
correlate with tumor growth. When a group of brain tumor-
bearing mice (n=5) were systemically injected with 
FA-pRNA-3WJ-si(Scrm) (1 mg/kg in 100 µL of PBS) for a 
total of three times over 6 days, the luciferase activity 
rapidly increased as the tumor grew indicating no effect of 
the control RNP on luciferase gene expression. However, 
luciferase activity from the group of mice (n=5) injected 
with FA-pRNA-3WJ-si(Luc) was observed to increase very 
slowly over time (FIG. 3B). After 3 injections, the luciferase 
activity from the mice injected with FA-pRNA-3WJ-si(Luc) 
was significantly lower (p=0.007) than that from the control 
group mice injected with FA-pRNA-3WJ-si(Scrm). The 
luciferase activity from the tested mice at day 13 post tumor 
implantation was mostly lower than that from the mice 
treated with FA-pRNA-3WJ-si(Scrm) (FIG. 3C). However, 
MRI revealed that the relative tumor size between those two 
groups was statistically insignificant (1.160±0.352 mm3 , 
s.e.m. with respect to 1.000±0.300 mm3 in negative control 
group) (p=-0.468, n=5) (FIG. 3D). When their luciferase 
activity was normalized by the tumor volumes, the relatively 
possess stem cell-like characteristics including a high level 
of CD44 expression, self-renewal capability and tumorige-
nicity when implanted in mouse brain (24-26). First, the 
30 CD44+ 1123 cells, maintained in serum-free sphere culture 
medium, were incubated in vitro with 200 nM of either 
FA-Alexa647-pRNA-3WJ or Alexa647-pRNA-3WJ RNPs. 
Flow cytometry analysis revealed higher FA-Alexa647-
pRNA-3WJ binding to the 1123 cells than control RNP 
35 (Alexa647-pRNA-3WJ) (FIG. 4A). Compared to PBS-
treated 1123 cells, 33.2±0.8% of CD44+ 1123 cells were 
positively associated with FA-Alexa647-pRNA-3WJ RNP. 
However, Alexa647-pRNA-3WJ control RNP was associ-
ated with only 12.7±0.4% of CD44+ 1123 cells. The differ-
40 ence between FA-Alexa647-pRNA-3WJ and Alexa647-
pRNA-3WJ was statistically significant (p<0.0001). 
For systemic assessment, a group of mice was then 
implanted with 1123 cells to induce intracranial brain tumor. 
Determined by MRI, mice bearing a similar size of brain 
45 tumors were then injected with PBS, Alexa647-pRNA-3WJ 
or FA-Alexa647-pRNA-3WJ RNPs in 100 µL of PBS 
through the tail vein. Fifteen hours post injection, the brains 
were dissected out and subjected to fluorescence imaging. 
Higher accumulation of FA-Alexa64 7-pRNA-3 WJ RNP was 
50 observed in the tumor region, while less accumulation of 
Alexa647 signal was observed from the brains treated with 
either control RNP (Alexa647-pRNA-3WJ) or PBS (FIG. 
4B). When two different dosages of FA-Alexa647-pRNA-
3WJ RNPs (20 or 100 pig/mouse) were tested in a group of 
55 mice bearing small sized tumors, fluorescence signals were 
proportional to the amount of RNPs injected (Supplemen-
tary FIG. 8). These observations suggests that FA-Alexa647-
pRNA-3WJ RNP can also recognize and target human 
glioblastoma stem cells and their derived tumor cells 
60 through FA-FR specific interaction. Throughout these stud-
ies, a fluorescence signal from the groups treated with 
FA-free 3WJ-pRNA control RNP was also observed 
although the extents were always lower than the groups 
treated with FA-3WJ-pRNA RNP. This might be explained 
65 by the nature of tumor induced from human patient derived 
stem cell-like glioblastoma cells, in which the aggressive 
hypervasculature leaves a large portion of blood vessels as 
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"leaky" as they are poorly finished before forming a tight 
junction of the BBB, also called the EPR (enhanced perme-
ability and retention) effect (27). 
To assess the biodistribution profile of the pRNA-3WJ 
RNP throughout the body after systemic administration, 5 
major internal organs, including heart, lung, liver, spleen and 
kidney, were also collected together with brain and subjected 
to fluorescence imaging. Compared to brain, no significant 
fluorescence signal was detected from the internal organs 
except kidney (FIG. 4C). The biodistribution profile of 10 
FA-pRNA-3WJ RNP after its systemic administration was 
consistent with the previous report (28), in that FA-conju-
gated drugs that failed to target tumor cells are rapidly 
cleared from a mouse body (t112 <l O min) through the kidney, 
reducing the safety concern of unbound pRNA-3WJ nano- 15 
particles circulating in the blood (7, 12-14). 
For successful clinical application of pRNA-3WJ RNP for 
human glioblastoma detection and treatment, it was critical 
to evaluate its capability to access brain tumor cells by 
discriminating them from adjacent normal brain cells, and to 20 
have favorable biodistribution. To address those two goals, 
the most critical checkpoints deciding the drugability of the 
pRNA-3WJ nanoparticles, we employed an orthotropic 
intracranial glioblastoma model system in mice. According 
to our observations, it was clear that FA-conjugated 25 
FA-pRNA-3WJ RNP can target human glioblastoma cells 
through FA-FR specific interaction-mediated endocytosis by 
distinguishing glioma cells from adjacent normal brain cells. 
A series of in vitro experiments indicated that such targeting 
in vivo was not obviously a result of non-specific accumu- 30 
lation for two reasons: 1) association of FA-pRNA-3WJ 
RNP with glioblastoma cells was ligand-dependent; and 2) 
the association was mediated through FA-FR specific inter-
action, since free folate pre-treatment interfered with the 
specific interaction between FA and FRs on the targeted 35 
cells. This suggests that FA-pRNA-3WJ RNP can target and 
accumulate in FR+ glioblastoma cells. Taken together with 
the fact that our brain imaging data were collected 15 hrs 
post injection of FA-3WJ RNA nanoparticles and the 
luciferase gene silencing effect was seen for days, these data 40 
suggest that FA-pRNA-3WJ RNP can survive in the body by 
retaining the chemical integrity of cargo siRNA until it 
reaches the brain. Most importantly, the therapeutic delivery 
by the FA-3WJ RNA nanoparticles was clearly demon-
strated by targeting endogenous luciferase mRNAs as a 45 
reporter system (FIG. 3). The decreased luciferase activity 
observed from a group of mice injected with FA-3WJ-
pRNA-si(Luc) RNP clearly answered questions towards the 
capability of the FA-3WJ RNP regarding: 1) specific target-
ing to brain tumor cells; 2) internalization into brain tumor 50 
cells; and 3) releasing the functional moiety (siRNA against 
luciferase mRNA). In addition, the targeting capability of 
pRNA-3WJ nanoparticles for both brain tumor cells and 
glioblastoma stem cells through a FA-FR mediated manner 
will overcome the weak point of conventional brain tumor 55 
therapies which largely relies on surgical debulking and 
less-specific toxic drugs with radiation. In summary, our 
current study successfully demonstrated the drugability of 
FA-conjugated pRNA-3WJ RNP as therapeutic gene deliv-
ery for clinical applications to meet the urgent need of new 60 
strategies to target and kill both glioblastoma stem cells and 
their derived tumor cells. Due to the ease and flexibility of 
modification of each RNA module, any drug conjugation 
and siRNA can be loaded to the RNP as therapeutic func-
tionalities. Recently, microRNAs have been found to 65 
involve in pathological process in glioblastoma making 
them as promising therapeutic targets (29-32). Since size 
24 
and working mechanism of miRNAs are similar to those of 
siRNAs (21), therapeutic miRNAs also can be considered to 
be loaded onto the pRNA-3WJ-RNP. 
Methods 
Construction of FA-Alexa647-pRNA-3Wj-si(Luc) RNP 
Multifunctional pRNA-3WJ RNP was prepared as previ-
ously described (7,12,13,22) with slight modifications. In 
brief, three RNA modules, named a3 wJ (5'-UUGCCAUGU-
GUAUGUGGG-3' (SEQ ID NO: 1)), b3 wJ (5'-CCCA-
CAUACUUUGUUGAUCC-3' (SEQ ID NO: 2)), and c3 wJ 
(5'-GGAUCAAUCAUGGCAA-3' (SEQ ID NO: 3)), were 
transcribed in vitro or synthesized chemically using 2'-F 
modified nucleotides and purified separately to homogene-
ity. For the current study, each RNA module was further 
modified as following: module a3 wJ was extended with 
luciferase siRNA sequences sense: 5'-CUUACGCUGA-
GUACUUCGAUU-3' (SEQ ID NO: 4) and anti-sense: 
5'-UCGAAGUACUCAGCGUAAGUU-3' (SEQ ID NO: 5), 
or scrambled as negative control; module b3 wJ was conju-
gated with FA at the 3' end; and module c3 wJ was conjugated 
with fluorophore Alexa647 (Alexa Fluor® 647, Invitrogen) 
at the 3' end. The three RNA modules were mixed at equal 
molar ratio to form one-step self-assembly. The self-as-
sembled FA-Alexa647-pRNA-3WJ-si(Luc) RNPs were 
purified from 6 M urea-containing PAGE and frozen at -80° 
C. after reconstituted in PBS. To obtain the designated 
concentration for each experiment, the RNPs were further 
diluted in PBS before use. 
Characterization of Self-Assembled FA-Alexa647-pRNA-
3WJ-si(Luc) RNP 
Three dimensional structure and shape of the final form of 
self-assembled FA-Alexa647-pRNA-3WJ-si(Luc) RNP was 
analyzed by atomic force microscopy (AFM) imaging as 
described previously.7 •12•13•22 Apparent hydrodynamic sizes 
and zeta potential of pre-assembled FA-Alexa647-pRNA-
3 WJ-si(Luc) RNP (1.5 µM) in PBS buffer was measured by 
Zetasizer nano-ZS (Malvern Instrument) at 25° C. The laser 
wavelength was 633 nm. The data were obtained from three 
independent measurements. 
Human Glioblastoma Cells and Human Patient-Derived 
Glioblastoma Stem Cells 
Human glioblastoma cells, U87EGFRvIII and 
U87EGFRvIII-Luc (expressing luciferase reporter gene), 
were obtained from Dr. Webster Cavenee (Ludwig Cancer 
Institute, San Diego, Calif.). Both cells were maintained in 
DMEM/10% FBS/penicillin/streptomycin. Human glioblas-
toma patient-derived glioblastoma stem cell "1123" was 
cultured in DMEM/F12 (Invitrogen) supplemented with 
B27 (1:50), heparin (5 mg/mL), basic FGF (bFGF) (20 
ng/mL), and EGF (20 ng/mL). Growth factors (bFGF and 
EGF) were added twice a week (24). 
Intracranial Human Glioblastoma Xenografts from Human 
Glioblastoma Cells and Human Patient-Derived Glioblas-
toma Stem Cells 
Six weeks old athymic female nu/nu mice (Jackson Labo-
ratory, Bar Harbor, Me.) were housed and handled in accor-
dance with the Subcommittee on Research Animal Care of 
the Ohio State University guidelines approved by the Insti-
tutional Review Board. All mice were fed folate-free diet 
(Harlan, Indianapolis, Ind.) for at least two weeks before 
tumor implantation. Intracranial human glioblastoma xeno-
graft tumor was induced by implanting human glioblastoma 
cell U87EGFRvIII or human patient-derived glioblastoma 
stem cells (lxl05 cells per mouse), as described previously 
(33). Two weeks post intracranial tumor implantation, the 
location and size of the implanted tumors were determined 
by magnetic resonance imaging (MRI). 
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Magnetic Resonance Imaging (MRI) for Location and Size 
of Implanted Brain Tumor in Mice 
On the indicated day post-surgery of intracranial tumor 
injection, the location and size of the implanted tumors were 
determined by magnetic resonance imaging (MRI). Mouse 5 
was anesthetized with 2.5% isoflurane mixed with 1 Umin 
carbogen (95% 0 2 with 5% CO2 ), then maintained with 1 % 
isoflurane thereafter. Maintaining core temperature using a 
warm water bath, imaging was performed using a Bruker 
Biospin 94/30 magnet (Bruker Biospin, Karlsruhe, Ger- 10 
many). Mice were injected with Magnevist, gadolinium-
based contrast agent (Bayer Health Care Pharmaceuticals, 
Wayne, N.J.) by an i.p. administration with 0.5 mmol/kg 
dose, then positioned in the magnet. T2-weighted RARE 
imaging was collected using a sequence (TR=3524 ms, 15 
TE=36 ms, rare factor=8, navgs=2, FOV=20x20 mm, 0.5 
mm slice thickness). Region-of-interest (ROI) was manually 
outlined based on contrast in signal intensity between brain 
and tumor tissue. 
Fluorescence Confocal Microscopy for In Vitro and In Vivo 20 
RNP Binding 
For the in vitro targeting test ofpRNA-3WJ RNP, 2xl03 
of U87EGFRvIII (malignant human glioblastoma) cells in 
200 µL were plated in Lab-TekII 8-well chamber slide 
(Nurre, Rochester, N.Y.). The next day, the cells were 25 
washed with PBS and incubated with 200 nM of either 
FA-Alexa647-pRNA-3WJ RNP or control RNP (Alexa647-
pRNA-3WJ) in 200 µL of culture media for 2 hrs at 37° C. 
in a CO2 incubator. To block cellular FRs by free folate, 
PBS-washed cells were pre-treated with 1 mM free folate in 30 
200 µL of culture media for 1 hr at 3 7° C. in a CO2 incubator 
before RNP treatment. After washing with PBS, the RNP-
treated cells were fixed in 4% paraformaldehyde (PFA) 
solution for 2 hrs at 4° C. The cytoskeleton of the fixed cells 
was stained by Alexa Fluor 488 Phalloidin (Invitrogen, 35 
Grand Island, N.Y.) for 30 min at room temperature and the 
nucleus stained with 0.01% DAPI solution for 10 min at 
room temperature. The cells were then rinsed with PBS for 
3xl 0 min and mounted with PermaFluor Aqueous Mounting 
Medium (Thermo Scientific). Fluorescence microscopy was 40 
performed using Olympus 4-filter-based Fluo View FVl 000-
Filter Confocal Microscope System (Olympus Corp.) at the 
wavelengths of 461 nm (for the cell nucleus stained by 
DAPI), 530 nm (for the cytoskeleton stained by Alexa Fluor 
488 Phalloidin) and 665 nm (fortheAlexa647). Images were 45 
analyzed by Olympus FluoView Viewer software ver. 4.0 
(Olympus). For in vivo targeting, the brain tumor xenograft 
collected 15 hrs after RNP injection was fixed in 4% PFA 
with 10% sucrose in PBS overnight at 4° C. and embedded 
in Tissue-Tek® O.C.T. compound (Sakura Finetek USA, 50 
Inc., Torrance, Calif.) for frozen sectioning (10 µm thick). 
The sectioned samples were mounted by ProLong® Gold 
Antifade Reagent with DAPI (Life Technologies Corpora-
tion, Carlsbad, Calif.) overnight. The fluorescent images 
were obtained using FluoView FVl000-Filter Confocal 55 
Microscope System (Olympus Corp.). 
Flow Cytometry for In Vitro RNP Binding 
Flow cytometry analysis was performed for in vitro 
targeting by pRNA-3WJ RNP in malignant human glioblas-
toma (U87EGFRvIII) and glioblastoma stem cells (1123). 60 
The cells were plated in 6-well plate one day before RNP 
binding. After washing with PBS, the cells were incubated 
with 200 nM of either FA-Alexa647-pRNA-3WJ RNP or 
Alexa647-pRNA-3WJ RNP in 200 µL of culture media for 
2 hrs at 37° C. in a CO2 incubator. For blocking cellular FRs 65 
by free folate, the PBS-washed cells were pre-treated with 1 
mM of free folate in 200 µL of culture media for 1 hr in 3 7° 
26 
C. CO2 incubator before RNP treatment. After washing with 
PBS, the cells were harvested by trypsinization and fixed in 
4% PFA solution for 2 hrs at 4° C. The cells were washed 
with PBS for 3 times at room temperature, then subjected to 
Flow Cytometry analysis using BD FACS Aria-III Cell 
Sorter. The data were analyzed by FlowJo 7.6.1 software. 
Systemic Injection ofRNPs to Intracranial Human Glioblas-
toma Xenograft Tumor Bearing Mice 
Based on the MRI evaluation taken one day before RNP 
injection, a group of mice bearing similarly sized tumors at 
similar location was selected for systemic injection ofRNPs. 
Designated amount of RNPs (1 mg/kg of mouse body 
weight) prepared in 100 µL of PBS were injected through 
mouse tail vein. After 15 hrs of RNP injection, the brains 
were dissected out and subjected to fluorescence imaging. 
Tumor volume calculated from MRI was also used to 
normalize fluorescence intensity or luciferase activity for 
each mouse as described below. 
Fluorescence Imaging on Human Glioblastoma Xenograft 
Mouse Brain Tumor 
To investigate the delivery ofpRNA-3WJ RNPs in vivo, 
a brain fluorescence imaging study was performed after tail 
vein injection into mice bearing brain tumor. The mice were 
sacrificed by cervical dislocation under anesthesia 15 hrs 
post injection, and brains were dissected out of mice. 
Fluorescence signals were detected from the dissected brains 
using IVIS Lumina Series III Pre-clinical In Vivo Imaging 
System (Perkin Elmer, Waltham, Mass.) with excitation at 
640 nm and emission at 660 nm for 2 min exposure. The 
fluorescence intensity was expressed as Mean Radiant Effi-
ciency [p/s/cm2/sr]/[µW/cm2 ], then normalized by tumor 
volume (mm3). PBS injected mice were used as fluorescence 
negative control. Major internal organs together with brain 
from the harvested mice were collected and subjected to 
fluorescence imaging for assessment of biodistribution pro-
file study. 
Bioluminescence Whole Body Imaging for Luciferase 
Activity 
To investigate the siRNA delivery and silencing effect of 
pRNA-3WJ RNPs in vivo, U87EGFRvIII-Luc cell-induced 
brain tumor was prepared into two groups of mice (n=5). At 
5, 7 and 9 days post-surgery, 1 mg/kg of mouse body weight 
of FA-Alexa647-pRNA-3WJ-si(Luc) RNP (or siScrm as 
negative control) was injected through the mouse tail vein in 
100 µL of PBS. After each injection, mice were subjected to 
bioluminescence whole body imaging to detect the endog-
enous luciferase expression level. Mice were injected with 
75 mg/kg Luciferin (Perkin Elmer, Waltham, Mass.), and 
anesthetized. Bioluminescence from the anesthetized mice 
was detected by ZFOV-24 zoom lens-installed IVIS Lumina 
Series III Pre-clinical In Vivo Imaging System (Perkin 
Elmer, Waltham, Mass.). The luminescence intensity was 
expressed as Averaged Radiance [p/s/cm2/sr], then normal-
ized by tumor volume (mm3). 
Statistical Analysis 
All statistical analyses comparing groups of mice treated 
with test and control RNPs were performed by either 
ANO VA or student t-test. p<0.05 was considered significant. 
Example 2 
This study is to determine the specific recognition and 
binding capability ofFA-3WJ-LNA-anti-miR21 RNAnano-
particles (RNP) towards human glioblastoma cells (FIG. 
9A), firstly FA-specific association between FA-3WJ-LNA-
miR21 conjugated with Alexa647 fluorescent dye and 
human patient-derived glioblastoma cell GBM30 was 
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assessed in vitro (FIG. 9B). The nanoparticle contains a 
stand of 5'-+G+A+T+A+A+G+C+T CTC CCG GCC GCC 
ATG GCC GCG GGA T-3' (SEQ ID NO: 7) (underlined 
sequence is 8-mer anti-miR21 LNA). 
The cells plated in 6-well plate one day before RNP 5 
binding were washed with PBS and incubated with 200 nM 
ofFA-3WJ-LNA-miR21-Alexa647 RNP for 2 hrs at 37° C. 
28 
(FIG. 11). The image shows successful internalization of 
FA-3WJ-LNA-miR21-Alexa647 RNP into GBM30 cells 
and accumulation in cytoplasm not much in nucleus. Since 
LNA-miR21 will work against mature miR-21 in cytoplasm 
to show its small RNA interfering activity, the cytoplasmic 
distribution of FA-3WJ-LNA-miR21-Alexa647 RNP prom-
ises the drugability in target therapy of glioblastoma. 
Alexa647 was expressed in red peudocolor. The cytoskel-
eton of the fixed cells was stained by Alexa Fluor 488 
in a CO2 incubator. After three times of washing with PBS, 
the cells were harvested by trypsinization and fixed in 4% 
PFA solution for 2 hrs at 4° C. and subjected to Flow 
Cytometry analysis using BD FACS Aria-III Cell Sorter. The 
cells were identified by staining actin filaments with Phal-
loidin-Alexa488. Comparison to FA-free control RNP (3WJ-
Alexa647), flow cytometry analysis showed a higher asso-
ciation in FA-3WJ-LNA-miR21-Alexa647 (23.1 %) (student 
t-test, p<0.001, n=3). Extra moiety of LNA-miR21 did not 
affect the specific binding to the GBM30 cells, since 
FA-3WJ-Alexa647 RNP showed similar level of association 
(21.4%) to the FA-3WJ-LNA-miR21-Alexa647 (23.1%). 
10 Phalloidin (Invitrogen, Grand Island, N.Y.) and the nucleus 
stained with 0.01 % DAPI solution. Fluorescence micros-
copy was performed using Olympus 4-filter-based FluoView 
FVl000-Filter Confocal Microscope System (Olympus 
Corp.) at the wavelengths of 461 nm (for the cell nucleus 
15 stained by DAPI), 530 nm (for the cytoskeleton stained by 
Alexa Fluor 488 Phalloidin) and 665 nm (for the Alexa647). 
Images were analyzed by Olympus FluoView Viewer soft-
ware ver. 4.0 (Olympus). The fluorescent images were 
obtained using FluoView FVl000-Filter Confocal Micro-
20 scope System (Olympus Corp.). 
Example 3 
Example 5 
This study shows anti-tumor effect of systemically deliv-
ered FA-3WJ-LNA-miR21 RNP in human glioblastoma 
cells derived tumor in vivo (FIG. 12). For in vivo test, 
intracranial tumor in mice was induced by implanting GBM-
Luc cells expressing luciferase gene which enables the 
tracing of tumor size change. Bioluminescence signal mea-
In this study, the folate receptor (FR)-dependent specific 
binding ofFA-3WJ-LNA-miR21-Alexa647 RNPto GBM30 
cells was further confirmed by visualizing the Alexa647 25 
signal from surface-cultured GBM30 cells treated with 
FA-3WJ-LNA-miR21-Alexa647 RNP under confocal fluo-
rescence microscope (FIG. 10). For the in vitro targeting test 
ofFA-3WJ-LNA-miR21-Alexa647 RNP, 2x103 ofGBM30 
cells in 200 µL were plated in Lab-Tek II 8-well chamber 
slide. The next day, the cells were washed with PBS and 
incubated with 200 nM of either FA-3WJ-LNA-miR21-
Alexa647 RNP or control RNP (3WJ-Alexa647) in 200 µL 
30 sured from the resulted brain tumor is expected to correlate 
with tumor growth. To establish in vivo mouse model, 
GBM30-Luc cells-induced brain tumor was prepared into 
two groups of mice (n=5). At 14 days post-surgery, 1 mg/kg 
of mouse body weight of FA-3WJ-LNA-miR21 RNP (or of culture media for 2 hrs at 37° C. in a CO2 incubator. The 
cytoskeleton of the fixed cells was stained by Alexa Fluor 
488 Phalloidin (Invitrogen, Grand Island, N.Y.) for 30 min 
35 FA-3WJ-LNA-SC as negative control) was injected through 
the mouse tail vein in 100 µL of PBS for total of five times. 
After each injection, mice were subjected to biolumines-
cence whole body imaging to detect the endogenous 
luciferase expression level. Mice were injected with 75 
at room temperature and the nucleus stained with 0.01 % 
DAPI solution for 10 min at room temperature. The cells 
were then rinsed with PBS for 3x10 min and mounted with 
PermaFluor Aqueous Mounting Medium (Thermo Scien-
tific). Fluorescence microscopy was performed using Olym-
pus 4-filter-based Fluo View FVl 000-Filter Confocal Micro-
scope System (Olympus Corp.). Higher fluorescence 
intensity of Alexa647 dye was observed from GBM30 cells 
treated with FA-3WJ-LNA-miR21-Alexa647 RNP than 
those with control RNP (3 WJ-Alexa64 7) lacking FA. Again, 
the FA-dependent association was not affected by the pres-
ence of LNA-miR21 sequences, since the FA-3WJ-LNA-
miR21-Alexa647 RNP showed comparable association with 
3WJ-Alexa647. When FRs of GBM30 cells were pre-
masked by incubating with 1 mM free-folate for 1 hr of 
culture before the RNP treatment, the association between 
FA-3WJ-LNA-miR21-Alexa647 RNP and GBM30 cells 
was abolished to an extent similar to the negative control 
3WJ-Alexa647 RNP. Taken together with data shown in 
FIG. 9, it indicated that the association between FA-3WJ-
LNA-miR21-Alexa647 RNP and GBM30 cells was FR 
dependent medicated by the FA conjugated to the RNP. 
Yellow arrow indicates the specific localization ofFA-3WJ-
LNA-miR21-Alexa647 RNP in GBM30 cells, which is 60 
presented with magnified view in FIG. 11. 
Example 4 
40 mg/kg Luciferin (Perkin Elmer, Waltham, Mass.), and anes-
thetized. Bioluminescence from the anesthetized mice was 
detected by ZFOV-24 zoom lens-installed IVIS Lumina 
Series III Pre-clinical In Vivo Imaging System (Perkin 
Elmer, Waltham, Mass.). The luminescence intensity was 
45 expressed as Averaged Radiance [p/s/cm2 ;/sr]. When a 
group of brain tumor-bearing mice (n=5) were systemically 
injected with FA-3WJ-LNA-miR21 (1 mg/kg in 100 JAL of 
PBS) for five times over 10 days, the luciferase activity 
rapidly decreased compared to the mice group injected with 
50 FA-3WJ-LNA-SC control RNP, indicating the anti-tumor 
effect ofFA-3WJ-LNA-miR21. as the tumor grew indicating 
no effect of the control RNP on luciferase gene expression. 
FIG. 12A shows representative in vivo MRI images for 
tumor volume and bioluminescence intensity for luciferase 
55 activity from both FA-3WJ-LNA-miR21 or FA-3WJ-LNA-
SC after five injections. FIG. 12B shows tumor volumes 
calculated from mean fluorescence intensity compared to 
scrambled control group after five injections, p=0.023 (n=5). 
Example 6 
This study shows the distribution of FA-3WJ-LNA- 65 
miR21-Alexa647 RNP in GBM30 cells after 2 hrs of incu-
bation was visualized by confocal fluorescent microscopy 
This study shows the Knock-down of endogenous miR-21 
in mouse tumor by systemically delivered FA-3WJ-LNA-
miR21 (FIG. 13). In this study, LNA-miR21 sequences 
conjugated to FA-3WJ-LNA-miR21 RNP is expected to 
silence endogenous miR-21 in mouse tumor induced by 
GBM30 cells. After five times of systemic administration of 
US 10,584,144 B2 
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FA-3WJ-LNA-miR21 RNP, the tumor was dissected out of 
mouse brain. Total RNA was extracted from the tumor tissue 
with Trizol reagent according to the manufacture's protocol. 
The expression level ofmiR-21 was determined by TaqMan 
MicroRNA expression Reverse-transcription analysis kit. 5 
snoRNA U6 was used as normalization internal control. 
Non-tumor brains serve to show endogenous level of miR-
21 in normal brain cells. GBM30 cells-induced tumor 
30 
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compared to non-tumor region. When the mouse tumors 10 
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Example 7 20 
This study shows the regulation of miR-21 by systemi-
cally delivered FA-3WJ-LNA-miR21 induced apoptotic 
pathway through recovery of Pten protein expression (FIG. 
14). In this study, Pten expression has been reported to be 25 
down regulated in glioblastoma, and identified previously as 
a primary silencing target of over-expressed miR-21 in 
glioblastoma. Data in FIG. 14 successfully demonstrated the 
anti-miR-21 silencing effect of to FA-3WJ-LNA-miR21 
RNP. To evaluate the miR-21 silencing effect in the down 30 
stream miR-21 targets, western blotting analysis was per-
formed on total proteins extracted from mouse tumors after 
systemically injection of FA-3WJ-LNA-miR21 RNP. FIG. 
14A refers to Western blotting identified up-regulation of 
Pten protein expression in the mouse tumor treated with to 35 
FA-3WJ-LNA-miR21 RNP. The increased Pten expression 
resulted suppression of Akt activity, a primary down stream 
target of Pten pathway, which activated apoptosis pathway. 
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in tumor cells to tumor regression as observed in FIG. 12. 40 
The image data in this study was analyzed by ImageJ 
software. Pten expression was increased at least more than 
four times in the mouse tumors treated with to FA-3WJ-
LNA-miR21 RNP compared to those with to FA-3WJ-LNA-
SC RNP (p=0.022, n=5). 45 12. Shu, D.; Shu, Y.; Haque, F.; Abdelmawla, S.; Guo, P. 
Example 8 
This study shows knock-down of endogenous miR-21 in 
mouse tumor by systemically delivered FA-3WJ-LNA- 50 
miR21 improved overall survival of brain tumor-bearing 
mice (FIG. 15). In this study, Kaplan-Meyer survival curve 
was used to compare overall survival rates of two brain 
tumor-bearing mice groups treated with to FA-3WJ-LNA-
miR21 RNP and negative control RNP (to FA-3WJ-LNA- 55 
SC) after total of five time systemic administrations. As 
shown above data, apoptosis in mouse brain tumor region 
activated by the systemically injected FA-3WJ-LNA-miR21 
RNP significantly improved the survival rate (p=0.0023, 
n=5). Median survival rate of the FA-3WJ-LNA-miR21 60 
RNP treated mice group was 23 days, while the mice group 
treated with FA-3WJ-LNA-SC RNP showed 19 days of 
median survival rate. 
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<160> NUMBER OF SEQ ID NOS, 19 
<210> SEQ ID NO 1 
<211> LENGTH, 18 
<212> TYPE, RNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
uugccaugug uauguggg 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 




<210> SEQ ID NO 3 
<211> LENGTH, 16 
<212> TYPE, RNA 
33 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 10,584,144 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
ggaucaauca uggcaa 
<210> SEQ ID NO 4 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 4 
cuuacgcuga guacuucgau u 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
ucgaaguacu cagcguaagu u 
<210> SEQ ID NO 6 
<211> LENGTH, 43 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 6 
uugccaugug uaugugggau cccgcggcca uggcggccgg gag 
<210> SEQ ID NO 7 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 7 
gataagctct cccggccgcc atggccgcgg gat 
<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 8 








<210> SEQ ID NO 9 
<211> LENGTH, 23 
<212> TYPE, RNA 
35 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 
uacccuguag aaccgaauuu gug 
<210> SEQ ID NO 10 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 10 
uucaaguaau ccaggauagg cu 
<210> SEQ ID NO 11 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 11 
ugagguagua gguuguauag uu 
<210> SEQ ID NO 12 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 12 
aggcggagac uugggcaauu g 
<210> SEQ ID NO 13 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 13 
uggcaguguc uuagcugguu gu 
<210> SEQ ID NO 14 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 14 
cguguucaca gcggaccuug au 








<211> LENGTH, 23 
<212> TYPE, RNA 
37 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 15 
guccaguuuu cccaggaauc ccu 
<210> SEQ ID NO 16 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 16 
aacauucauu gcugucggug ggu 
<210> SEQ ID NO 17 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 17 
agcactttct cccggccgcc atggccgcgg gat 
<210> SEQ ID NO 18 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 18 
atttgcacct cccggccgcc atggccgcgg gat 
<210> SEQ ID NO 19 
<211> LENGTH, 39 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 19 







What is claimed is: 55 
1. An artificial RNA nanostructure molecule, wherein the 
molecule comprises a multiple branched RNA junction 
motif comprising at least one RNA oligonucleotide, and a 
brain tumor targeting module, wherein the module is 
coupled to the RNA junction motif, wherein the multiple 60 
branched RNA comprises a nucleotide sequence 5'-UUG 
CCA UGU GUA UGU GGG AUC CCG CGG CCA UGG 
CGG CCG GGA G-3' (SEQ ID NO: 6) or 5'-GATAAGCT 
CTC CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID 
NO: 7). 
3. The molecule of claim 1, wherein the RNA oligonucle-
otide comprises at least one chemical modification at the 2' 
position. 
2. The molecule of claim 1 further comprising at least one 
bioactive agent coupled to the RNA junction motif. 
4. The molecule of claim 3, wherein the modification 
comprises 2' Fluoro, 2' Amine, 2' O-Methyl, or a combina-
tion thereof. 
5. The molecule of claim 1, wherein the motif is a 
three-branched RNA junction motif. 
6. The molecule of claim 1, wherein the diameter of the 
65 molecule is at least about 40 nm or less. 
7. The molecule of claim 1, wherein the molecule has a 
zeta potential ranging from about -50 m V to about 50 m V. 
US 10,584,144 B2 
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8. The molecule of claim 5, wherein a branch of the 
three-branched RNA junction motif comprises an a3WJ 
RNA module (SEQ ID NO: 1); a b3WJ RNA module (SEQ 
ID NO: 2); a c3WJ RNA module (SEQ ID NO: 3); or a 
combination thereof. 
9. The molecule of claim 1, wherein RNA oligonucle-
otides comprises at least 6 nucleotides in length. 
10. The molecule of claim 1, wherein the brain tumor 
targeting module comprises a ligand that binds to at least one 
brain tumor cell surface marker. 
10 
11. The molecule of claim 10, wherein the ligand binds to 
40 
19. The molecule of claim 15, wherein the bioactive agent 
is a miRNA molecule for a miRNA comprising let-7a, 
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miR-
181b. 
20. The molecule of claim 18, wherein the anti-miRNA 
comprises an anti-miRNA locked nucleic acid (LNA) mol-
ecule. 
21. The molecule of claim 20, wherein the anti-miRNA 
LNA molecule comprises sequence 5'-GATAAGCT-3', 
5'-AGCACTTT-3', or 5'-ATTTGCAC-3'. 
a folate receptor, an EGFR, a transferrin receptor, an RGD, 
or a combination thereof. 
12. The molecule of claim 10, wherein the ligand com-
prises an aptamer. 
13. The molecule of claim 11, wherein the aptamer binds 
to EGFR, PDGFR, folate receptor, or a combination thereof. 
22. The molecule of claim 15, wherein the mRNA mol-
ecule encodes a protein comprising VEGF, EGFR, POK, 
AKT, AGT, RAF, RAS, MAPK, ERK, MGMT, MMP-2, 
15 
MMP-9, PDGF, PDGFR, IGF-1, HGF, mTOR, Cox-2 or 
TGF~l. 
14. The molecule of claim 1, wherein the targeting 
module comprises a folate. 
15. The molecule of claim 2, wherein the bioactive agent 
comprises a drug, a therapeutic agent, a fluorescent dye, a 20 
chemical, an siRNA, an miRNA, an anti-miRNA, a 
ribozyme RNA, an antisense RNA or a combination thereof. 
16. The molecule of claim 2, wherein the bioactive agent 
is directed to a brain tumor marker. 
17. The molecule of claim 15, wherein the microRNA 25 
sequence is at least 6 nucleotide in length. 
18. The molecule of claim 15, wherein the bioactive agent 
is an anti-miRNAmolecule for a miRNAcomprising miR-9, 
miR-l0b, miR-21, miR-17, or miR-26. 
23. The molecule of claim 15, wherein the siRNA binds 
to a mRNA molecule that encodes RAS, cMET, HER2, 
MDM2, PIK3CA, AKT, CDK4, or a combination thereof. 
24. A nucleic acid composition, comprising a therapeuti-
cally effective amount of the RNA nano structure of claim 1. 
25. The composition of claim 24, further comprising a 
pharmaceutically acceptable carrier. 
26. The artificial RNA nanostructure of claim 1, wherein 
the RNA nanostructure comprises a nanoparticle delivery 
system. 
27. The nanoparticle delivery system of claim 26, further 
comprising a pharmaceutically acceptable carrier. 
* * * * * 
